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"Die naturwissenschaftliche Frage ist die logische Hypothese, welche von einem 
bekannten Gesetz durch Analogie und Induktion weiterschreitet; die Antwort 
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I. Summary 
Colorectal carcinoma is one of the global leading causes of tumor-associated death. The 
management of colorectal cancer currently involves surgical and non-surgical 
interventions. For patients with locally restricted tumor stages, appropriate surgical 
approach to remove the primary lesion is currently the mainstay of curative treatments. 
For hepatic, pulmonary or peritoneal metastatic colorectal cancer, systemic therapy 
represents the backbone of treatment and surgical resection in selected patients with 
resectable metastases (pulmonary, hepatic, peritoneal) may also lead to improved 
survival. Additionally, recent advances in genomic technologies, immunology, and cell 
biology have led to novel understandings about the modulations of the 
microenvironment in all stages of colorectal carcinoma.  
The main objective of this dissertation was on the one hand to prove the effect of 
laparoscopic approach for colorectal carcinoma management. On the other hand, from 
an experimental perspective, it is to reveal that the inflammatory microenvironment 
might be associated with tumorigenesis in parasite infestation. Additionally, because 
bone marrow-derived mesenchymal stem cells (MSC) are important components that 
could mediate interactions between the inflammatory microenvironment and cancer cells, 
this study also demonstrated the molecular mechanisms associated with irradiation and 
cellular interactions of tumor cells and MSC cells.  
The first manuscript investigated surgical strategies for primary colorectal cancer (Ref.1) 
and revealed that improved oncological control was provided with complete mesocolic 
excision (CME) for colonic cancer, comparable to precise local lymph node dissection 
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particularly in the technically advanced surgical procedure of laparoscopic left 
hemicolectomy. 
Nevertheless, surgical intervention in elderly patients are still associated with elevated 
postoperative morbidity and mortality as well as dysfunction. Thus, in the second paper, 
it was investigated that colorectal cancer treatment in patients with elevated 
perioperative risk caused more surgical complications. Additionally, it was demonstrated 
that laparoscopic (minimally invasive) surgery was superior in oncologic outcome and 
survival, especially for those with renal or respiratory dysfunction as well as stage III 
carcinoma (Ref.2)  
 
To introduce the aspect of inflammation on cancer development, the third paper shows a 
clinical case collection of schistosomal colorectal carcinoma and its prognostic factors 
and clinicopathological characteristics. Immune reactions against schistosomal eggs in 
the colorectal mucosa lead to inflammatory disease, and the repetitive inflammatory 
reaction is to be relevant for carcinogenesis. Correlation of clinical parameters showed, 
that patients with rectosigmoid schistosomiasis presented an elevated cancer antigen 
125 (CA-125) level and the majority of these patients were at the earlier stage of 
carcinoma). (Ref.3)  
Additionally, radiotherapy not only induces cytoreduction of colorectal cancer but also 
remodels the tumor microenvironment by promoting tumor-associated tropism reaction 
of peripheral BM-MSC circulation. However, the function of irradiation mediated 
recruited BM-MSCs and local MSCs were poorly defined, they do play a crucial role in 
immune microenvironment modulation (Ref.4). Indeed, the role of bone marrow-derived 
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mesenchymal stem cells remained controversial in tumor development even without 
radiation intervention: Previously, it was reported that BM-MSC modulates the immune 
response of lymphocytes, resulting in immune tolerance which might induce local 
recurrence or distant metastasis. In contrast, BM-MSC is capable to release diverse 
cytokines/chemokines and possess cytotoxicity effect against the tumor. In the fourth 
paper, it was shown that bone marrow-derived mesenchymal stem cells could potentially 
enhance the anticancer activity of colorectal cancer radiotherapy. 
This cumulative dissertation is based on 4 articles which were published in peer-review 
scientific journals in the timeframe from 2015 to 2018 (JCR and 
http://www.scimagojr.com):   
Ref.1-Feng, H., Zhao, X., Zhang, Z., Han, D., Mao, Z., Lu, A., & Thasler, W. E. 
(2016). Laparoscopic Complete Mesocolic Excision for Stage II/III Left-Sided Colon 
Cancers: A Prospective Study and Comparison with D3 Lymph Node 
Dissection. Journal of Laparoendoscopic & Advanced Surgical Techniques, 26(8), 
606-613. (impact factor: 1.322#, Quartiles: Surgery, Q2)  
 
Ref.2- Feng H, Schiergens TS, Mao ZH, Zhao J, Shen X, Lu AG, Thasler WE. Long-
term outcomes and propensity score matching analysis: rectal cancer resection for 
patients with elevated preoperative risk. Oncotarget. 2017 Apr 11;8(15):25679. 
(impact factor: 5.168*, Quartiles: Oncology, Q1)  
 
Ref.3- Feng, H., Lu, A., Zhao, X., Han, D., Zhao, J., Shi, L., Schiergens TS, Lee SM, 
Zhang WP, ... & Thasler, W. E. (2015). Comparison of non-schistosomal 
rectosigmoid cancer and schistosomal rectosigmoid cancer.  World Journal of 
Gastroenterology, 21(23), 7225-7232. (impact factor: 3.411#, Quartiles: 
gastroenterology and hepatology, Q2) 
 
Ref.4- Feng, H., Zhao, J., Schiergens TS, Wang, P., Ou, B., Rami Al-Sayegh, Li, M., 
Lu, A., Yin, S., & Thasler, W. E. (2018) Bone marrow-derived mesenchymal stromal 
cells promote colorectal cancer cell death under low-dose irradiation. British Journal 
of Cancer. 2018 Jan 2; Epub. (impact factor: 5.922#, Quartiles: Medicine, Q2) 
 
#2018 &*2017 Journal Citation Reports® (Clarivate Analytics, 2018 & Clarivate Analytics, 2019) 
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The present dissertation evaluates the management of CRC in four different aspects:  
• surgical technique of lymph node dissection (Ref.1), 
• the oncological outcome of minimally invasive surgery (Ref.2),  
• the  influence of chronic inflammation in carcinogenesis (Ref.3), 
• the modulation of the immune microenvironment by MSCs (Ref.4),  
In addition to the published results, the experimental work during the last four years 
explored the mechanisms of immune modulation in colorectal cancer liver metastases. 
Currently, the experiments investigate the function of CXCR6+iNKT cells in metastatic 
colorectal cancers and the modulation of the microenvironment by the crosstalk of 
Kupffer cells and hepatic resident invariant nature killer T cells in liver metastases. (see 
outlook)  
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1. Introduction 
Over the past two decades, the incidence of colorectal cancer declined by about 2-4% 
per year in both genders, with the pace accelerating in more recent decade from 2004 to 
2013, which might be attributed to alterations in risk factors and screening programs 
(Edwards et al, 2010), especially colonoscopy screening and the removal of 
precancerous polyps (Siegel et al, 2012). However, colorectal carcinoma is still the third 
leading cause of death according to the most recently released data from the American 
Cancer Society (ACS, Edwards, et al, 2017). Furthermore, the incidence increases each 
year in younger adults (< 50 years old) (SEER et al, 2012). Globally, colorectal 
carcinoma is also listed as the third most frequent carcinoma diagnosed in both genders 
(Jemal et al, 2011), especially in European countries, Australia, East Asia, and North 
America according to the World Health Organization (WHO) GLOBOCAN database 
(http://globocan.iarc.fr/Pages/Map.aspx).  
1.1 Management of CRC from a surgical perspective 
Concerning primary colorectal cancer, surgery is currently the most appropriate choice 
of curative treatment (Young et al, 2014). The current management is a complete 
mesocolic excision (CME) procedure for colonic carcinoma or the total mesorectal 
excision (TME) approach of the rectum to remove the tumor as well as the lymphatic 
drainage basin of the affected colonic segment or rectum, including the major vascular 
pedicle. However, CME and TME are associated with an elevated risk of postoperative 
morbidity and mortality (Beets et al, 2016). In patients with comorbidities and advanced 
age, the mortality rate is as high as 10-15%, the overall morbidity rate increased from 19% 
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to 26% (Antoniou et al, 2015). The increasing awareness of postoperative morbidity, as 
well as the influence of quality of life after colorectal cancer surgery, induced an 
increasing interest in surgical approach selection among conventional open surgery, 
laparoscopic surgery, robotic surgery, and transanal endoscopic surgery with the aim to 
be as radical as possible concerning the tumor but less invasive concerning the patient 
Especially the implementation of minimally invasive surgical techniques, the comparative 
study of conventional and laparoscopic surgical approach for colorectal carcinoma has 
been conducted for decades.  
Concerning the laparoscopic approach, constant effort (e.g. Natural-orifice transluminal 
endoscopic surgery (NOTES)) has been paid to minimize the surgical trauma and 
reduce surgery associated morbidity. Meanwhile, numerous studies focused on 
perioperative management such as postoperative pain, mortality within 30 days, and 
length of hospital stay. According to these studies, laparoscopy showed favorable 
outcomes. Additionally, there was no difference in oncological outcomes when 
comparing conventional open surgery to laparoscopic surgery. Furthermore, elderly 
patients do profit from laparoscopic surgery even in their oncologic outcome.  
For localized primary colorectal cancer (Stage I and II), the 5-year overall survival rate is 
around 90%. However, those patients only account for approximately 2/5 of all colorectal 
cancer patients (Siegel et al, 2017). 1/5 to 1/4 of patients were stage IV carcinoma when 
diagnosed, 15–25% of patients were with synchronous liver metastasis (Nordlinger et al, 
2009, Lykoudis et al, 2014, Adam et al, 2015), 25% of patients showed metachronous 
liver metastases. 
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Even for CRLM, liver resection is still the most effective treatment to offer long-term 
disease-free survival (Jones et al, 2017).  However, the 5-year overall survival rate 
declined rapidly to 14% (Siegel et al, 2017) and only a minority of 20% of patients are 
suitable for surgery (Vatandoust et al. 2015, Garden et al. 2006) and 30% of these 
patients will develop recurrence (Jones et al, 2012). It is quite a challenge when 
colorectal cancer has already spread to distant sites to form metastasis, which made 
multimodal management of CRC necessary. 
1.2  Comprehensive Management of CRC and CRLM 
Adjuvant or neoadjuvant chemotherapy regimens are usually recommended for patients 
with lymph node metastases. However, plenty of patients with metastasis are not 
suitable for surgical therapeutic strategies due to morbidities, organ dysfunction, or non-
hepatic disease progression. (Garden et al., 2006; Alberts et al., 2005). Alternative 
treatment options for tumor control e.g. locally ablative regimens prolonged survival. 
Treatment modalities currently being used include:  
1) chemotherapy seem to be the optimal option for improving symptoms and extending 
life expectancy (Table 1). In addition, the use of chemotherapy in a neoadjuvant setting 
allows increasing patients with CRLM eligible for resection by 3-20 % (Misiakos et al, 
2011; García et al,2015). However, the efficacy was still modest, and these therapies 
were also associated with significant toxicities. Inspiringly, to date, multidisciplinary 
research aims to prolong survival, as well as to increase the percentage of patients 
previously considered unresectable to be significantly down-staged and eligible for 
hepatic resection.  
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2) Targeted therapy, utilizing monoclonal antibodies such as cetuximab, bevacizumab, 
and panitumumab, has led to improved oncological outcomes. The development of 
molecular targeted therapies accelerated with the understanding of the molecular 
pathways that mediate cancer cell proliferation, invasion, and angiopoiesis. Prolongation 
of patient survival and improvement in the quality of life has been associated with the 
use of these therapeutic strategies. (García et al,2015) 
3) Ablative techniques, such as radiofrequency ablation (RFA) (Cirocchi et al. 2012), 
irreversible electroporation (Fruhling et al.2017), use heating probes to destroy tumors 
within the liver. The 5-year survival rates of CRLM after RFA range from 20.0% to 48.5%. 
The local progression rate is 8.8%~ 40.0%. 
4) Techniques to improve resectability include portal vein embolization (PVE) (Wicherts 
et al. 2010), Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy 
(ALPPS) (Vennarecci et al. 2014), and two-stage hepatectomy. PVE before 
major/extended hepatectomy could increase Future Liver Remnant (FLR), to convert 
unresectable to resectable tumors. Though infrequently being used, two-stage 
hepatectomy is a vital and curative surgical approach for highly selected CRLM patients 
with bilobar multinodular hepatic metastasis.  
5) Irradiation, intensity-modulated radiation therapy (IMRT, Krishnan et al., 2006) and 
Stereotactic Body Radiation Therapy (SBRT) are approaches that can reduce the 
damage of radiation-induced liver disease (RILD) for hepatic metastasis(Lawrence et al., 
1992; Cheng et al., 2002).  
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6) Cancer immunotherapy: Food and Drug Administration (FDA) approval of anti-
programmed cell death protein 1 (anti-PD-1), anti-PD-L1, and of anti-Cytotoxic T-
lymphocyte-associated antigen 4 (anti-CTLA4) for the treatment of metastatic cancer 
has engendered novel awareness among surgeons and physicians of anticancer effect 
of checkpoint inhibitor (Sharma et al. 2015, Pardoll et al. 2012). Additionally, remarkable 
efforts of the pharmaceuticals above were shown in urinary cancer, gynecological 
cancer, and Hodgkin’s lymphoma, even after therapeutic failure of conventional 
therapies. Despite clinic success in a variety of malignant tumors, evidence in colorectal 
cancer is lacking (Jacobs et al, 2015). Regarding the complicated tumor 
microenvironment of colorectal cancer, it is essential to investigate the immune 
mechanism and its modulation in the management of colorectal cancer. 
 
 
Figure 1: Multimodal management of colorectal cancer. 
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Table 1: Overview of non-surgical treatment options in colorectal cancer  
 
Chemotherapy  Target therapy Immunotherapy  
 5-Fluorouracil (5-FU) 
Small-molecule drugs  
(such as VEGF Receptor 2 inhibitor) 
Monoclonal antibodies 
 capecitabine (Xeloda)  Serine/threonine kinase inhibitors 
Adoptive cell therapy (such as 
CAR T-Cell Therapies) 
 irinotecan (Camptosar) 
 
Monoclonal antibodies 
Regorafenib (Stivarga) 
Toll-like receptor (TLR) agonists 
 
Leucovorin 
(folinic acid) 
Cetuximab target EGFR Cancer vaccines 
 
oxaliplatin (Eloxatin) 
Vectibix (panitumumab) 
 target EGFR 
Bevacizumab targets VEGF 
Interleukin-2 (IL-2) & tumor-
infiltrating lymphocytes   
 Aflibercept 
ramucirumab (Cyramza) 
aflibercept (Zaltrap) 
Immune checkpoint inhibitors 
(such as PD-1/PD-L1 inhibitors 
and CTLA-4 inhibitors) 
 Tipiracil    
 
1.3 Tumor microenvironment and immune modulation in CRC  
Among the multimodal management of colorectal cancer treatment, immunotherapy per 
se, (not only immune checkpoint inhibitors but also CAR-T and monoclonal antibody-
based therapy) is hopefully changing the therapeutic option for patients. Recently, the 
American FDA has approved immunotherapy mostly in the second line setting for 
multiple stage IV cancer after progression on chemotherapy. Nevertheless, disease 
progression has been reported after the treatment of immunotherapy in non-small cell 
lung cancer, as well as head& neck malignancy (Saâda-Bouzid E et al. 2017). In fact, 
the tumor microenvironment is the vital area of the crosstalk among cancer cells, stromal 
cells, and the immune system via cytokines and chemokines. In response to certain 
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chemokines, various immune cell subsets and mesenchymal stem cells (MSCs) migrate 
into the microenvironment, differentiate, and regulate tumor immune responses in a 
spatiotemporal manner. It is suspected that MSCs can regulate both, adaptive as well as 
innate immunity and exert immune modulatory activity, which confer tremendous 
potential for clinic application. MSCs are able to secrete alterative cytokines and 
chemokines to possess anti-tumor properties (Pommey et al, Galipeau et al, 2006; 
Hendijani et al, Javanmard et al, Liotta et al, 2015). However, from the other side, MSC 
could also construct a suppressive immune microenvironment, resulting in immune 
tolerance and the promotion of cancer cell proliferation, which increases the risk of 
tumor relapse (Houthuijzen et al, 2012; Chen et al, 2015). Furthermore, the secretion of 
chemokines and cytokines, the interaction of MSCs and tumor cells under radiation 
could complete and enhance the efficacy of the radiotherapy.  
 
Figure 2: chemokine receptors and ligand pairings 
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2. Objectives 
The translational research presented in this dissertation aimed to investigate the 
management of colorectal cancer from clinical and experimental aspects.   
From a surgical perspective: It has been stated by several randomized clinical trials 
that the oncological outcomes and long-term survival rates were equivalents between 
the open and laparoscopic approach to treat rectal carcinoma. In addition, shorter 
hospital stay, rapid recovery, less hemorrhage, and reduced complications rates were 
achieved by a laparoscopic approach. However, surgery is related to substantial 
morbidity and mortality for patients with co-morbidities and elder patients. The first 
session of the dissertation aimed to analyze the outcome of patients with rectal cancer 
and elevated operative risk, either after conventional or laparoscopic approach.  
From the experimental perspective: the aim of this part was to evaluate the interaction of 
inflammatory microenvironment and tumorigenesis as a therapeutic target. BM-MSC are 
important components which are able to mediate interactions between the inflammatory 
microenvironment and cancer cells. This study also demonstrated the tumor modulatory 
function of MSCs under radiation. Considering pluripotency and cancer tropism reaction 
of mesenchymal stromal cells, our study supposed that mesenchymal stromal cells 
could either sensitize or obtund the radiotherapy effect in colorectal carcinoma.  
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3. Summary of results 
Paper I:  Management of CRC from the perspective of surgical technique  
Feng, H., Zhao, X., Zhang, Z., Han, D., Mao, Z., Lu, A., & Thasler, W. E. (2016). 
Laparoscopic Complete Mesocolic Excision for Stage II/III Left-Sided Colon Cancers: 
A Prospective Study and Comparison with D3 Lymph Node Dissection. Journal of 
Laparoendoscopic & Advanced Surgical Techniques, 26(8), 606-613. (impact 
factor: 1.322#, Quartiles: Surgery, Q2)  
 
Comparative study was performed among laparoscopic D3 lymphadenectomy and 
complete mesocolic excision (CME) to analyze the resemblance and distinction among 
different approaches for stage II and stage III colonic carcinoma left hemicolectomy. 
1. The quality of lymph node dissection was comparable. The mean mesenteric area of 
the specimen was significant different (P < .0001), with 5730mm2 in a superior rectal 
artery (SRA) preserving D3 lymph node dissection, 8145 mm2 in non-preserving 
approach, and 8745 mm2 in CME group.  
2. Despite the quantity of lymphadenectomy measured by the lymph node count was 
higher in CME specimens, log odds of positive lymph nodes (LODDS) or positive nodes 
or lymph node ratio (LNR) were similar among the groups.  
3. The difference among perioperative morbidity measured by the recovery time of 
bowel function was insignificant. Although operative time in D3 lymphadenectomy was 
longer, the variance was insignificant. Concerning the anastomotic leakage (p = 0.34) 
and vascular comorbidity (p = 0.64), the differences were insignificant either. 
 
 
 
18 
 
Paper II: Management of CRC from the perspective of comorbidity  
Feng H, Schiergens TS, Mao ZH, Zhao J, Shen X, Lu AG, Thasler WE. Long-term 
outcomes and propensity score matching analysis: rectal cancer resection for 
patients with elevated preoperative risk. Oncotarget. 2017 Apr 11;8(15):25679. 
(impact factor: 5.168*, Quartiles: Oncology, Q1)  
 
This paper discussed how personalized risk assessment has significant implications for 
colorectal cancer surgical practice and management. Total mesorectal excision (TME) 
for rectal carcinoma is relevant to comorbidity and mortality, especially in patients 
experiencing comorbidities as well as elder patients. This study investigated the 
prognosis in these patients who went through conventional or laparoscopic rectal 
resection. The retrospective study recruited 132 high operative risk patients after 
propensity score matching from 2007 to 2011 with the elevated operative risk patient 
defining as Cr-POSSUM > 5% plus other risk factors.  
1. The overall complication rate: conventional approach (71 %) > laparoscopic rectal 
resection (41%, p=0.0005).   
2. Conventional open surgery was positively relevant to advanced Clavien-Dindo 
grading (p=0.02).  
3. There was a positive correlation (p=0.01) between Clavien grading and Cr-POSSUM;   
4. Patients with stage III-IV colorectal cancer and patients with preoperative respiratory 
disease or renal dysfunction experienced better overall survival rate through the 
laparoscopic approach (p< 0.0001, p=0.03, p=0.049). 
Locoregional recurrence rate was similar between laparoscopic (6%) and conventional 
(8%) surgical approaches. No significant difference could be detected between patients 
underwent various approaches in stage I∼II (p = 0.13, HR 0.5565, 95%CI 0.26-1.19). 
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However, the overall survival rate was elevated significantly in the laparoscopic surgery 
group with stage III-IV carcinoma (p<0.0001). These results demonstrated the 
advantages of the laparoscopic approach for elevated operative risk patients with rectal 
carcinoma 
 
Paper III:  
 
Feng, H., Lu, A., Zhao, X., Han, D., Zhao, J., Shi, L., Schiergens TS, Lee SM, 
Zhang WP, ... & Thasler, W. E. (2015). Comparison of non-schistosomal 
rectosigmoid cancer and schistosomal rectosigmoid cancer.  World Journal of 
Gastroenterology, 21(23), 7225-7232. (impact factor: 3.411#, Quartiles: 
gastroenterology and hepatology, Q2) 
 
 
The retrospective study recruited 26 rectosigmoid carcinoma patients with colonic 
schistosomiasis diagnosed via endoscopy and pathological evaluations from 2009 to 
2013. The clinicopathological features were compared for patients with non-
schistosomal rectosigmoid carcinoma and schistosomal rectosigmoid carcinoma. 
1. Patients with rectosigmoid schistosomiasis expressed a significantly elevated level of 
biomarker CA-125 and the majority presented with an earlier stage of cancer(p=0.003).  
2. Different morphological characteristics of endoscopic finding----60% presented as 
fungating mass polyps, 30% were congestive and ulcerative polyps, cauliflower-like 
masses and annular masses were presented as 30% and 10%, respectively. 
3. Thickened walls of the bowls, as well as linear and tram-track calcifications, could be 
detected by computed tomography (CT) scans. 
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Paper IV:  
Feng, H., Zhao, J., Schiergens TS, Wang, P., Ou, B., Rami Al-Sayegh, Li, M., Lu, A., 
Yin, S., & Thasler, W. E. (2018) Bone marrow-derived mesenchymal stromal cells 
promote colorectal cancer cell death under low-dose irradiation. British Journal of 
Cancer. 2018 Jan 2; Epub. (impact factor: 5.922*, Quartiles: Medicine, Q2) 
 
This paper discussed if the application of combined therapy of hBM-MSCs and 
radiotherapy has implications for colorectal cancer treatment. In the present study, 3D 
culture modules, co-cultivation modules, and colorectal tumor organoids were 
established. The flow cytometry and enzyme-linked immunosorbent array were applied 
to analyze the cytokines and chemokine secretion in mesenchymal stromal cells under 
low-dose radiation. X-ray was used to modulate the irradiating microenvironment.   
1. In vitro, BM-MSCs could induce the epithelial-mesenchymal transitions (EMT) 
progression of colorectal cancer cells;  
2. Low-dose ionizing radiation-induced BM-MSCs to release TNF-α and IFN-γ and 
present anticancer effect in 2D and 3D co-cultivation system.  
3. Certain cytokine (TNF-α, IFN-γ) secreted by BM-MSCs under irradiation lead to 
impaired proliferation and apoptosis of colorectal cancer cells in 3D and co-culture 
system. 
4. Irradiation of the co-cultivation system leads to caspase3 cleavage of the cancer cells. 
Additionally, it attenuated PI3K/AKT and ERK phosphorylation in colorectal cancer cells.  
Taken together, potentially, BM-MSCs enhanced the effect of radiation associated 
cytotoxicity against colorectal carcinoma. Additionally, CRC patients might benefit from 
the conjunction of BM-MSC with radiotherapy.  
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Laparoscopic Complete Mesocolic Excision
for Stage II/III Left-Sided Colon Cancers:
A Prospective Study and Comparison
with D3 Lymph Node Dissection
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Abstract
Background: To investigate the similarities and differences of laparoscopic complete mesocolic excision
(CME) to a colon resection with a D3 lymphadenectomy for the stage II/III left-sided colon carcinoma.
Methods: Patients between July 2011 and August 2014 were randomized into D3 and CME groups. Mesenteric
area, log odds of positive lymph nodes (LODDS), and other operative parameters were collected and assessed.
Results: The average specimen sizes were 5730– 828mm2 in superior rectal artery (SRA)-preserving D3,
8145– 1022mm2 in SRA-nonpreserving D3, and 8745 – 1039mm2 in the CME group; the differences were
significant (P < .0001). The number of lymph nodes collected from CME specimens was larger, but the CME
specimens did not contain an elevated value of LODDS or positive nodes or lymph node ratio (LNR). There
were also no significant differences between recovery times of bowel function. Although it took more operation
time in D3 approach, especially in SRA-preserving D3 operation, the difference was not significant. Concerning
the leakage rate (P= .34) and vessel-related complications (P= .64), there were no significant differences either.
Conclusions: Both standard D3 resection and CME could achieve a high quality of mesocolic plane grade for
stage II/III colon cancer. The LODDS and LNR were comparable, and those were not relevant to mesenteric size.
Introduction
During the last decades, from the first laparoscopichemicolectomy performed by Jacob in 19931 and the D3
excision in 1996 to the concept of complete mesocolic ex-
cision (CME), which was raised in 2009,2 the radical dis-
section rate of colonic cancer has been improved to pursue a
clearer and adequate surgical margin, lower local recurrence
rate, and better long-term postoperative outcome.3,4
Based on the anatomy and embryology, CME has already
been the standard procedure for colon cancer excision, which
ensures the complete removal of the mesocolon by ‘‘high li-
gation of central vascular,’’ ‘‘cutting off main vessel,’’ and
‘‘central lymph node dissection.’’ However, D3 excision has
also achieved more than 15 years of satisfactory clinical out-
comes in Asia, especially in Japan, China, and South Korea.5
D3 excision underlined the dissection of lymph nodes that
were located at the root of the central vessels.6,7 This study is to
investigate the similarities and differences of laparoscopic
CME to a colon resection with a D3 lymphadenectomy for the
stage II/III left-sided colon carcinoma.
Materials and Methods
Patient selection
A prospective trial was performed in the Shanghai Mini-
mally Invasive Surgery Center between July 2011 andAugust
2014. Forty-one cases with colorectal cancer went through
laparoscopic left-sided colon resection and were randomly
divided into two groups: the D3 and CME group. Primary
outcome (lymph node ratio [LNR]) and secondary outcomes
(size of mesentery specimen, positive lymph nodes, leakage,
etc.) were compared between the two groups.
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The inclusion criteria were patients with descending colon,
sigmoid-descending colon junction identified by preopera-
tive histopathological biopsy, computed tomography (CT)
scan, MRI, and endoscopy findings; with preoperative tumor
stage II or III according to the AJCC 7th, emergency resec-
tions were excluded, so that 38 patients were included in this
study. Video and photographs of the operation and the re-
sected samples were assessed by three independent profes-
sional observers to evaluate the quality of the approaches.
Informed consent was obtained from all patients. The pri-
mary outcome of this study was the LNR, which ranges from
0.2 to 0.4; a previous study demonstrated that the values were
well spread across 0.2–0.4, with a mean of 0.28 and standard
deviation (SD) of 0.27 and 20 patients per arm. An independent
t-test would provide 80% power to detect a difference between
groups at two-sided a of 0.05. Assuming a dropout rate of 20%,
we thus aimed at enrolling 20 subjects in each arm.
Eligible patients were randomly allocated to CME or D3
colorectal surgery. To obtain a balanced distribution of dif-
ferent surgical procedures in the two groups, randomization
lists were generated by a computer program, assuming that all
patients had the same probability of undergoing CME or D3
surgery. Randomization by individual random numbers was
also performed. Assignments were made by means of sealed
sequenced masked envelopes that were opened, before the
induction of anesthesia, by a nurse unaware of the trial design.
Ethics statement
Protocol approval for all research performed was obtained
from the Medical Ethics Committee of Shanghai Ruijin
Hospital according to the Declaration of Helsinki.
Operation procedure
Laparoscopic CME in left hemicolectomy. The dissection
started at the left colic artery (LCA), and the root of inferior
mesenteric artery (IMA) was then ligated with Ham-o-Locks,
preserving the preaortic fascia (PAF)8,9 and the superior hy-
pogastric plexus (SHP)10 (Fig. 1A, B). Dissection was per-
formed until the pancreas was detected after an incision of the
FIG. 1. Laparoscopic CME in left hemicolectomy. (A,B) the dissection and ligation of IMA; (C,D,E), IMV exposure
ligation; (F), left lateral peritoneal reflection mobilization. CME, complete mesocolic excision; EPS, extraperitoneal space;
IMA, inferior mesenteric artery; IMV, inferior mesenteric vein; LCA, left colic artery; L-GA, left gonadal artery; L-GV, left
gonadal vein; Lig Treitz, Treitz ligament; LRC, left retrocolic space; MCA, middle colic artery; MCV, middle colic vein;
PAF, preaortic fascia; SCA, sigmoid artery; SCL, splenocolic ligament; SHP, superior hypogastric plexus.
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Treitz ligament (LigTreitz) (Fig. 1C). After separating the right
gastrocolic ligament (RGL) and splenocolic ligament (SCL)
(Fig. 1D), the origin of the inferior mesenteric vein (IMV) was
ligated after dissecting the inferior edge of the pancreas
(Fig. 1E). Lymph nodes surrounding the mid-colic artery
(MCA) and its left branch were dissected, and the vessel was
ligated. The dissection of the splenic flexure area was laterally
followed by dissection of the left lateral peritoneal reflection,
colofascial and mesofascial plane mobilization, and dissection
of the peritoneal reflection at the base of mesosigmoid to the
extraperitoneal space (EPS) (Fig. 1F). The Toldt’s fascia was
dissected from the iliac ridge to the splenic flexure to dissect the
phrenicocolic ligament (PCL) and sustentaculum lienis, which
acted as a brassiere to the lower pole of the spleen.
Laparoscopic D3 lymph node dissection. The harvested
lymph nodes were mapped according to the Japanese guide-
line. According to this guideline, lymph nodes over the root
of IMA were defined as N3 lymph nodes,11 and therefore, the
D3 lymph node dissection was performed as follows12: for
the cancers of descending colon, and for those tumors whose
feeding vessels proximal to sigmoid colon were the first
branch of sigmoid colon artery (SCA), the root of IMA was
exposed with an ultrasonic surgical device. The LCA was
then exposed, clipped, and cut, however, the superior rectal
artery (SRA) was preserved—SRA-preserving D3. In the
other way (SRA-nonpreserving D3), the central vessel IMA
should be ligated at the root.13 After the lymph node (LN)
dissection, the mesentery of the sigmoid and descending
colon was mobilized posteriorly in a medial to lateral ap-
proach, maintaining the layer on the left ureter and gonadal
vessels14,15 (Fig. 2).
Calculation of mesenteric size
Previous studies measured the length of specimens, or used
softwares to measure the macroscopic area. Instead, this
study calculated the area of left mesocolon with a formula.
Important specimen parameters were included to reduce
measurement errors induced by the inconsistency of pro-
portional scale (Supplementary Fig. S1; Supplementary Data
are available online at www.liebertpub.com/lap).
Assessments of the operation
The plane of dissection was evaluated by a histopatholo-
gist on the basis of the presence and extent of any identifiable
mesocolic defect. The grading system referred to the system
reported by West et al.,16 including dissection in the meso-
colic plane (intact mesocolon), intramesocolic plane (sig-
nificant mesocolic defects that do not expose the muscularis
propria), or muscularis propria plane (significant and ex-
tensive defects that expose areas of muscularis propria).
Log odds of positive lymph nodes
First, the fresh specimens were examined by the surgeons,
the lymph nodes were carefully mapped according to their
location, and then, whether there were more lymph nodes that
remained was double checked by the pathology department.
The LNR was defined as the number of positive lymph nodes
divided by the number of examined lymph nodes (NELN).
Log odds of positive lymph nodes (LODDS) were classified
according to log (number of positive nodes + 0.5)/(number
of total examined nodes-positive nodes + 0.5) values as fol-
lows: LODDS0 (p-1.36), LODDS1 (-1.36 to -0.53), and
LODDS2 (q-0.53).17
Statistical methods
Logistic regression was performed to analyze the corre-
lation of mesentery sizes and LNR. A paired Student’s t-test
and ANOVA were also used. Analyses were performed with
Stat View 5.0 for Windows (SAS Institute, Inc., Cary, NC).
The v2 test or Fisher’s exact test was applied to analyze the
categorical variables, as appropriate. A probability (P) value
of <.05 was regarded as statistically significant.
Results
There was no significant difference in age (P = .35), gender
(P = .57), BMI (P= .54), tumor location (P = .20), ptumor
stage (P = .74), intraoperative blood loss (P = .46), and sple-
nic bleeding (P= .65) among these groups.
Assessment of plane grades
Eighteen cases were considered as mesocolic plane grade
in SRA-preserving D3 group, 19 cases were considered as
mesocolic plane grade in the SRA-nonpreserving D3 group. In
CME group, mesocolic plane grade and intramesocolic plane
grade were 19 and 1 cases; the differences between the two
groups were insignificant.
Mesentery size
The average specimen sizes were 5730 – 828mm2 (SRA-
preserving D3), 8145– 1022mm2 (SRA-nonpreserving D3),
FIG. 2. Schema of laparoscopic D3 left hemicolectomy.
The gray line shows the cutting strategy for SRA preser-
vation and the black line shows the cutting strategy of the
D3 dissection without SRA preservation. LCA, left colic
artery; SCA, sigmoid artery; SRA, superior rectal artery.
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and 8745– 1039mm2 (CME group), respectively. The dif-
ferences between SRA-preserving and SRA-nonpreserving
groups were significant (P < .0001), so were the differences
among the three groups (P< .0001). It was because that the
incisal margin should be *10 cm longitudinally in D3 ex-
cision, following the so-called 10 cm rule, the length was
measured by laparoscopic forceps during the operation.
However, there was no significant difference between the
SRA-nonpreserving group and CME group (P= .0538)
(Figs. 3 and 4).
Positive lymph node, LODDS, and LNR
More lymph nodes were harvested in SRA-nonpreserving
D3 and CME specimens compared to SRA-preserving D3
specimens (P1= .004, P = .05), but not between the former
two groups (P = .67) (Table 1 and Figs. 3 and 4). The LNRs
were 24%, 31%, and 25% in those groups and did not show a
significant difference (P = .75, P1= .57, P2 = .49). Further-
more, the regression analysis showed that the mesentery size
was related to total LN, but not to the LNR. Nine in 31 cases
of stage III patients had the positive center lymph nodes.
Interestingly, we also found unilateral double ureters in one
of the patients (Fig. 5C).
Other articles suggested that LODDS provide more valu-
able information than LNR independently of the NELN. In
the present study, there was no significant differences in
LODDS among each group (P = .80). And notably, LODDS
and LNR curves have a similar trend.
In this study, the distance between proximal margin/distal
margin and central vessel was measured soon after the fresh
specimens were collected, so were the Da and sample length.
FIG. 3. The correlation among area of mesentery (A), positive lymph node (B), and surgical procedures.
FIG. 4. The correlation among positive lymph node ratio (A), LODDS (B), and surgical procedures. LODDS, log odds of
positive lymph nodes.
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Table 1. Characteristics of Patients and Specimens
SRA-preserving
D3 (n= 20)
SRA-nonpreserving
D3 (n = 20) CME (n = 20) P
Age 58.1 66.8 61.8 P = .35
Gender (male/female) 3/8 7/6 7/7 P = .57
BMI (kg/m2) 25.8 26.2 26.9 P = .54
Tumor location
Descending colon 13 (1) 9 12
Splenic flexure 8 (1) 6 5 P = .20
Sigmoid-descending
colon junction
0 5 3
pTumor stage
II 11 8 10 P = .74
III 9 12 10
Area of mesentery (mm2) 5730– 828 8145– 1022 8745 – 1039 P < .0001, P1< .0001, P2= .0538
Sample length (cm) 24.6 28.2 31.2 P = .0001, P1= .0003, P2= .99
Minimum radius (mm) 110.8 119.8 118.4 P = .11, P1 = .08, P2= .64
Intraoperative blood loss (mL) 78.3 90.8 92.1 P = .18, P1 = .11, P2= .85
Splenic bleeding 1 3 2 P = .65, P1 = .38, P2= .57
Positive LN 2.65– 3.3 4.90 – 5.1 4.95 – 6.0 P = .52, P1 = .24, P2= .87
Total number of LN 10.2– 2.0 14.8 – 3.5 15.8 – 7.4 P = .05, P1 = .004, P2= .67
LNR 0.24– 0.3 0.31 – 0.3 0.25 – 0.3 P = .75, P1 = .57, P2= .49
LODDS
LODDS0 5 7 8 P = .80
LODDS1 6 2 2 P1 = .56, P2 = .57
LODDS2 9 11 10
PM, ED (mm) 105.5, 46.1 110.69, 47.69 111.14, 47.36
SinDa 0.79 0.92 0.94 P < .0001, P1< .0001, P2= .08
P1, P-value between SRA-preserving and SRA-nonpreserving D3; P2, P-value between SRA-nonpreserving D3 and CME; P, P-value
among the three groups.
CME, complete mesocolic excision; ED, excision edge; LN, lymph node; LRC, left retrocolic space; LNR, lymph node ratio; LODDS,
log odds of positive lymph nodes; PM, proximal margin mesocolon; SRA, superior rectal artery.
FIG. 5. (A) lymph node metastasis at the root of vessel; (B), accurate exposure of PRF and LRC; (C), ureter variation; (D),
variation of branch vessels of sigmoid and LCA. IMV, the inferior mesenteric vein; LCA, left colic artery; LRCS, left retrocolic
space; MRLN, mesenteric root lymph nodes; PRF, prerenal fascia; SCA, sigmoid artery; SRA, superior rectal artery.
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There were significant differences among the three groups
concerning the sina (P< .0001), but not between the SRA-
preserving group and CME group. Other data are shown in
Table 1.
Postoperative short-term outcomes
There was no significant difference in bowel function re-
covery time, liquid diet time, and postoperative analgesia
(P = .56) among these three groups (Table 2). It took more
operating time in D3 operation (SRA-preserving D3, 124.6
minutes, SRA-nonpreserving D3, 119.8 minutes, CME 119
minutes, P = .67), especially in SRA-preserving D3 opera-
tion, owing to the separation and dissection for SCA and
SRA, but the difference was not significant. We evaluated the
postoperative complications, respectively: one patient got
leakage 6 days after operation in the D3 group and one patient
got leakage 5 days after operation in the CME group
(P = .34). Concerning the vessel-associated complications,
there was no significant difference (P = .64).
Discussion
CME and D3, unified and complementary
In 2006, the Japanese Society for Cancer of Colon and
Rectum published the 7th edition guideline; the guideline
defined again the lymph node grouping and recommended the
same range for D3 dissection. A radical D3 lymph node dis-
section of colon cancer should be performed to remove the
paracolic lymph nodes (N1), intermediate lymph nodes (N2),
and central lymph nodes (N3).18 In 2010, the ChineseMinistry
of Health issued the Chinese standard for colorectal cancer
treatment,19 which recommended that lymph node dissection
for advanced colon cancers without distant metastasis should
cover the same three groups. For left-sided colon cancers, D3
dissection specially clears the lymph nodes located along the
root of IMA (between the origin of the artery and that of the
LCA). The advantage of D3 excision could be (1) to avoid
excess mobilization of the transverse colon for anastomosis
and (2) to preserve the normal sigmoid colon in view of
minimally invasive surgery. What is the difference between
the SRA-nonpreserving D3 and CME? Theoretically, they
should be equivalent procedures with the principles of both
procedures being the same. Rates for intact mesocolic plane
were both high as were lymph node yield, but both were sig-
nificantly greater in the CME specimens; however, lymph
node positivity rates were equivalent. It was postulated that the
differences between these specimens were likely related to the
technique adopted by each country. The Japanese D3 has
previously shown that positive lymph node spread rarely oc-
curs beyond 10 cm from the tumor and as such, D3 rarely
resects more than 10 cm from the tumor. The CME specimens
in contrast were significantly longer, and hence, the resulting
larger mesocolic surface area and lymph node counts. Survival
and local recurrence data are similarly impressive.
Both CME and D3 approach advocate careful dissection
along embryologic planes, resulting in a marked improve-
ment in the oncologic quality of the specimen without in-
creasing the postoperative complications or mortality rates.20
Compared to SRA-nonpreserving D3, the CME technique
usually includes removal of the next vascular arcade beyond
the 10 cm margin to ensure that there was no remaining re-
gional paracolic nodes; it probably also accounts for the
marked increased resected area of mesentery in CME spec-
imens.21 In our previous study, which included 31 cases with
left-sided colon cancer that underwent laparoscopic CME
between September 2010 and December 2012, the compli-
cations were observed in 4 cases (12.9%), the total number of
lymph nodes removed was 13.9 – 5.0, including 4.7 – 2.6
paracolic lymph nodes, 5.4 – 3.7 intermediate lymph nodes,
and 5.4 – 3.7 nodes at the mesocolic root.22
Center vessel ligation (CVL) and infarct layer dissection
are the key points of CME technology, the main vessel ties
are always performed at the root. The advantages of CVL are
showed in several studies, while controversial conclusions
also exist, which suggested no demonstrable benefit. Con-
sidering the harvested lymph nodes, several lines of evidence
suggested that lymph node metastasis is a stochastic, rather
than a stepwise, phenomenon,23 therefore, it is not surprising
that some clinical researches failed to identify a survival
benefit from extensive lymphadenectomy compared to stan-
dard resection, which suggested that a therapeutic benefit of
extensive lymphadenectomy in colon cancer may not be
convincing. That might also explain the similarly impressive
reported outcomes of left-sided colonic tumors in both CME
and D3 excision. This study showed that mesentery size was
not relevant to LNR or positive LN. As reported before,
significant longitudinal spread is rare, about 0% for left-sided
tumor; therefore, it was not surprising that the CME speci-
mens did not contain an increased number of positive nodes.
In contrast, Le Voyer et al. suggested that the number of total
lymph nodes was relevant to prognosis of colorectal cancer
although some of which were negative.24 Especially for pa-
tients with pN1 tumors, survival improved as the number of
collected lymph nodes increased. An absolute 23% im-
provement (90% vs. 67%) in a 5-year survival was achieved
if more than 40 lymph nodes were identified, compared with
those patients who had 10 or fewer nodes.24
Table 2. Short-Term Postoperative Outcomes
SRA-preserving D3 (n= 20) SRA-nonpreserving D3 (n = 20) CME (n = 20) P
Operation time 124.6 119.8 119.0 .67
Bowel function recovery 2.7 2.7 2.9 .81
Liquid diet 1.67 1.69 1.64 .98
Postoperative analgesia 2 2 4 .56
Leakage 0 1 2 .34
Vessel-related complication 0 1 1 .64
CME, complete mesocolic excision; SRA, superior rectal artery.
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Some strategies for laparoscopic CME in left
hemicolectomy
It is necessary to remove the perivascular sheath by sharp
dissection for better central vessel root exposure, especially
for patients with lymph node metastasis (Fig. 5A). Second,
following the accurate surgical planes and spaces is also quite
important, especially the mesofascial plane,25 retrofascial
interface, PAF, and LRC (Fig. 5B). Third, there are various
vascular alterations. For instance, there are 6 kinds of vari-
ations of the branch vessels of sigmoid and LCA,26 the routes
of ureters also have kinds of variations (Fig. 5C,D).
Splenic flexure mobilization. Around the splenic flexure,
Toldt’s fascia spreads to the dorsal side of pancreatic tail, and
so, if the surgeon separates splenic flexure followed by Toldt’s
fascia, this might naturally enter the dorsal side of pancreas,
which might damage the vessels and pancreatic structure.
There are two approaches to separate the splenic flexure, one is
lateral approach of splenic flexure mobilization (SFM-L),
which is to separate the Toldt’s fascia then upwards to splenic
flexure, the other; is to open gastrocolic ligament first and
gradually divide the left side toward splenic flexure, which is
also named anterior approach of splenic flexure mobilization
(SFM-A). In detail, in SFM-L, the surgeon would stand at the
right side of patients, after mobilization of the omental bursa
from the lateral side (close to the tail of the pancreas) was
performed. In SFM-A approach, the right-sided patient posi-
tion was changed to an anti-Trendelenburg position with the
surgeon standing between the patient’s legs. The camera
should also be moved from the supraumbilical to the trocar in
the middle abdomen to achieve sufficient distance to the
splenic flexure. However, the latter might be easier to distin-
guish the pancreatic tail with visual control, so as not to
damage the structure. It was suggested that there was a sig-
nificantly higher rate of intraoperative complications in the
SFM-L group compared to the SFM-A group. It is also re-
ported that a shorter operative time can be taken during the
medial to lateral approach (Supplementary Fig. S2).
Recognize PAF, retrofascial interface, and the meso-
fascial plane. There were prerenal fascia posterolateral to
the left mesocolon, PAF median to the left mesocolon, pa-
rietal layer of the pelvic fascia posterolateral to the mesor-
ectum, which continued at different sites. Peritoneum
resection was performed along the aorta to the top, the PAF is
exposed under the peritoneal connective tissue, which ex-
tends upward till the dorsal side of the duodenum and con-
tains autonomic nerve fibers inside.
Recently, Coffey et al. found that the peritoneal occurs
wherever the mesenteric organ is opposed to the retro-
peritoneum, so that to gain access to the mesofascial plane, a
peritonotomy of the peritoneal reflection in this location is
required.When this is lengthened, and the interface placed on
stretch, it might be possible to separate sharply the compo-
nents of the mesofascia interface without disrupting the in-
tegrity of either.27,28
It also showed the contiguity among the mesorectal fascia,
the mesosigmoidal fascia, and the left mesocolic fascia.29
Thus, these represent different regions of the same fascial
entity. In keeping with this, the mesorectal fascia, Gerota’s
fascia, and the anterior pararenal fascia are different regions
of the same entity.30
Preserve the SRA or not?
Both D3 and CME could get a high rate ofmesocolic plane
grade for stage II and stage III patients,31 and CME extends
longitudinal mesocolon resection. In this study, a long-term
follow-up and larger sample quantity would be essential. D3
excision is flexible in choosing whether to preserve SRA or
not, which was determined by the clinical preoperative
staging as well as intraoperative staging. SRA preservation
may reduce the anastomotic tension compared to the SRA-
nonpreserving D3 approach, so as to reduce the leakage
rate32; however, there were not enough evidences to show
whether it promotes early bowel function recovery. In con-
trast, it was also reported that SRA preservation could be
performed without compromising the quality of lymph node
dissection and relapse-free survival, but no advantage of
SRA-preserving approach was demonstrated.33 In addition,
the LCA might be absent in 12% patients,34 and so, CT re-
construction is recommended for the D3 approach.
In conclusion, both D3 and CME can achieve high quality
of mesocolic plane grade for stage II and stage III patients.
The LODDS and LNR were comparable and without sig-
nificant correlation with the mesenteric area.
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ABSTRACT
BACKGROUND: It is still controversial about the treatment strategy for rectal 
cancer patients with elevated operative risk and elder rectal cancer patients. 
METHODS: This study presented a retrospective single center experience in rectal 
cancer proctectomy for high operative risk patients. High operative risk patient was 
defined as Cr-POSSUM > 5% combined with associated risk factors. 220 in 1477 
consecutive patients met the inclusion criteria. 
RESULTS: 132 patients were selected (66:66) after propensity score matching. 
The total complication rate between conventional open rectal resection (71 %) 
and laparoscopic surgery (41%) was significantly different (p = 0.0005). There 
is a significantly positive correlation between open surgery and advanced Dindo 
Classification (p = 0.02). Cr-POSSUM is positively correlated with Dindo Classification 
(p = 0.01). There was no significant difference in survival rate among stage I~II, 
different age groups or different Cr-POSSUM score sub-groups. However, stage III-
IV tumor patients in laparoscopic group experienced improved overall survival rate. 
(p < 0.0001). For patients with preoperative pulmonary or renal disease, patients in 
laparoscopic group also had better long term prognosis (p = 0.03, p = 0.049). 
CONCLUSIONS: The results demonstrate the potential advantages of laparoscopic 
rectal cancer resection for high operative risk patients, especially for the patients with 
preoperative respiratory or renal disease and stage III cancer.
INTRODUCTION
Rectal cancer is associated with substantial 
morbidity and mortality, especially in elder patients and 
those with co-morbidities. Outcome after these surgeries 
depends both on modifiable factors, such as perioperative 
medical care, and on physiological tolerance of surgical 
trauma. Over the last two decades, we have seen a 
continuous improvement of the quality of laparoscopic 
surgery in rectal cancer, especially in specialized 
centers with longstanding experience and high annual 
volumes. Several studies that compared laparoscopic 
and conventional open resection for rectal cancer show 
no difference with respect to local recurrence or overall 
and disease-free survival after 3, 5 [1, 2] even 10 years 
[3], respectively. More recently, long-term data including 
the MRC CR07 [4], MRC CLASICC trial, Comparison of 
Open versus laparoscopic surgery for mid or low Rectal 
cancer After Neoadjuvant chemoradiotherapy (COREAN) 
trial [5], the Colorectal cancer laparoscopic or Open 
Resection (COLOR II) trial [6] have released long-term 
survival rates. Though some of the randomized control 
trials have included patients with elevated preoperative 
risk (American Society of Anesthesiologists classification 
3 and 4), these patients were generally recruited to clinical 
trials less often than younger patients and therefore 
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are under-represented in publications about cancer 
treatment [7]. Because of this heterogeneous, can these 
recommendations from major studies, such as laparoscopic 
rectal operations are safe and sound, be extrapolated to 
the fragile subset of patients with more comorbidity or 
do they need to be modified? The aim of this study is to 
analysis the survival and outcomes in patients with rectal 
cancer associated with high operative risk in conventional 
open rectal resection group (OpS) and laparoscopic rectal 
resection group (LaPS).
MATERIALS AND METHODS
Patients
 This study included all 1477 consecutive patients 
undergoing radical surgical resection for rectal cancer 
in a tertiary referral teaching hospital - Shanghai Ruijin 
Hospital between September 2007 and Nov 2011. 220 
patients were considered with high operative risk. 
Patients were admitted to Gastrointestinal Surgical 
Centre or Minimally Invasive Surgical Centre. Both 
centers belong to Department of General Surgery. The 
operative conditions, anesthesia management as well as 
perioperative management were at the same level. Both 
surgical teams had the same operative quality of rectal 
cancer. Emergency protectomy was excluded.
Diagnoses and tumor stage
 The diagnoses were made preoperatively and then 
confirmed by postoperative pathology. The tumor node 
metastasis (TNM) staging of colon and rectal cancer 
system (American Joint Committee on Cancer Manual, 
7th edition) was used. The criteria for neoadjuvant 
radiochemotherapy were patients with rectal cancer of the 
lower and middle third of the rectum and suspected T3 or 
T4 tumors and patients with pathological lymph nodes as 
demonstrated by CT or MRI-scan.
Surgical procedures and quality control
 Patient demographics were extracted routinely 
by trained registrars from the hospital records. Patients 
were assigned preoperatively to the laparoscopic or open 
approach based on clinical criteria and imaging, including 
chest radiograph, abdominal computed tomography, 
and colonoscopy etc. Patients’ preference had also been 
considered. Conversion cases were deemed necessary 
remained in the laparoscopic surgery group for all 
outcomes by intention-to-treat analysis. The preoperative 
preparation and the techniques of the procedures were 
described previously. With our experience from open 
total mesorectal excision, laparoscopic surgery was 
performed according to the same oncologic principles 
[8, 9]. Briefly, laparoscopic surgery was done with five 
trocars, the rectum was mobilized with monopolar cautery 
or an ultrasonic scalpel, dissecting between the visceral 
and parietal pelvic fascia without injuring the hypogastric 
nerves. Laparoscopic and open procedures were performed 
by four senior surgeons with their specialist team from 
the division of Gastrointestinal Surgery or division of 
Minimally Invasive Surgery in Ruijin Hospital. In the 
LapS group, surgery was performed by a systemic team 
of surgeons with abundant experience and expertise in 
conventional colorectal surgery and laparoscopic skills. 
In the OpS group, another fixed group of experienced 
surgeons specializing in colorectal surgery executed the 
surgery. [9] 
Statistical methods
 Analyses were performed with Stat View 5.0 for 
Windows (SAS Institute Inc., Cary, NC, USA). The Х2 
test or Fisher’s exact test was applied to analyze the 
categorical variables. The results were subjected to a 
nonparametric Mann-Whitney U test. A Student’s t-test 
was also used to analyze the intragroup differences. The 
Kaplan-Meier method was used to analyze the overall 
survival of patients; the log-rank test was used to compare 
patient survival between groups. Cox-regression model 
was used for multivariate analysis. Logistic regression 
was used to analyze the correlation of Cr-POSSUM and 
Dindo-Demartines-Clavien Classification. P < 0.05 was 
regarded as statistically significant.
Propensity score matching
Propensity score matching was applied to reduce 
the effect of treatment selection bias and potential 
confounding effect, thereby creating a quasi-randomized 
experiment. This matching is done using a generalized 
SAS macro that matches Ops to LapS at a 1:1 ratio, 
using an algorithm to maximize the number of propensity 
score match. Patients were selected based on this score 
calculating for baseline characteristics; that is age, gender, 
tumor size, tumor location, tumor stage, Cr-possum value 
and radiochemotherapy at baseline in patients. 
Risk evaluation
Patients with a predicted Colorectal Physiologic and 
Operative Severity Score for the enumeration of Mortality 
and Morbidity (Cr-POSSUM) ≥5% OR criteria below [10] 
were managed as ‘high operative risk’: 
1. Aged > 60 years 
 PLUS undergoing re-do surgery 
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 OR have acute or chronic renal impairment (sCr > 
130 μmol/L) 
 OR have diabetes mellitus 
 OR are strongly suspected clinically to have any 
significant risk  factor for the cardiac or respiratory 
disease. (e. g. chronic obstructive pulmonary disease, 
history of ischemic heart disease, congestive heart failure, 
arrhythmias, angina pectoris, or cardiac risk index > 12 
etc.) 
2. have shock of any cause, any age group.
Cr-POSSUM scores were calculated for each patient 
retrospectively from their medical records. The calculating 
software is freely available on the internet (http://www.
riskprediction.org.uk/index-cr.php, Risk Prediction in 
Surgery) 
RESULTS
 There was no significant difference between each 
group concerning the age (69±11.2 vs 68±12.1 years 
Table 1: The patient demographics and histopathological tumor assessment
Clinical or pathologic feature OpS (n = 66) LapS (n = 66) P-value 95%CI
Sex ratio ( Male: Female) 45:22 46:21 0.85 -0.1794-0.1491
Age (years) 69±11.2 68±12.1 0.59 -2.984-5.196
Body mass index (kg/m2) 28.1 27.9 0.44
pTumor stage (AJCC)
I 18 17
IIA 17 10
IIIB 6 12
IIIA 3 5 0.85 -0.2982-0.3588
IIIB 10 12
IIIC 4 7
IV 8 3
Lymph node metastasis 
N0 42 40
0.81N1 15 17
N≥2 9 9
Tumor size (diameter, cm) 3.60±1.58 3.57±0.84 0.92 -0.3812-0.4239
Tumor location from anal verge (cm) 6.18±1.94 6.36±2.06
0.54 -0.5259-0.9978Low-rectal (0~5cm) 23 35
Mid-rectal (6~10cm) 40 26
Upper-rectal (>10cm) 3 5
Type of surgery  
APR 44 49
LAR 18 15 0.28
Others 4 2
Chemo-and/or radiotherapy 23 26 0.61 -0.2204-0.1294
Stoma formed
 No 23 21
 Ileostomy 20 29 0.58
 Colostomy 23 16
Resection margin
R0 65 65
 R1 1 1 --
Total mesorectal excision 
 Complete 46 38
 Nearly complete 11 17 0.52
 Unknown 3 4
 Incomplete 6 7
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Table 2: Preoperative risk, postoperative complications and other outcomes 
Clinical or pathologic feature OpS (n=66) LapS (n=66) P-value
Preoperative risk
Cr-possum Score
~ 10 percent 29 36
10 ~ 20 percent 24 15 0.65
20~  percent 13 15
Undergoing re-do surgery 3 2
Acute or chronic renal impairment 18 12 0.30
Diabetes 13 8 0.34
Cardiac disease 33 21 0.051
  Respiratory disease 33 22 0.08
Cerebrovascular disease 2 1 -
Dindo-Demartines-Clavien Classification
  Dindo 1 33 41
  Dindo 2 24 9 0.92
  Dindo 3 7 14
  Dindo 4 2 2
Surgical complications
Anastomotic leakage 5 6 -
Prolong ileus 1 1 -
Intra-abdominal abscess 2 1 -
Urological complication 6 5 -
  (transurethrale catheter-related problem, urinary tract infection/retension, ureter leakage)
Perineal wound complication 9 2 0.03
  (wound dehiscence, wound infections, wound necrosis, abscess or delayed wound healing)
perforation 1 1 -
Gastrointestinal haemorrhage 2 3 -
Rectal stump abscess 4 1 0.37
DVT 0 1 -
General complications
Cardiac complication 4 3 -
Respiratory complication 10 2 0.03
Neurological symptoms 1 0 -
Renal complication 3 0 0.24
Ascites 0 1 -
Return to normal bowel function 5.5 4.0
30-day mortality 1 0 -
Cr-POSSUM=Colorectal Physiologic and Operative Severity Score for the enumeration of Mortality and Morbidity. DVT, 
deep vein thrombosis 
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old, p = 0.5907). The Body mass index (BMI) were 
28.1kg/m2 and 27.9kg/m2 (p = 0.437). The tumor size 
was 3.60±1.58cm and 3.57±0.84cm, respectively (p = 
0.916), and located in 6.18cm and 6.36cm from the anal 
verge. The tumor stage, postoperative radiochemotherapy, 
circumferential resection margin ( < 2mm) positivity 
(LapS 1of 66 [2%] vs OpS 1 of 66 [2%]), distal margin, 
macroscopic completeness of the resection (incomplete 
rate: LapS 9% vs OpS 10%), locoregional recurrence rate 
(LapS 4of 66 [6%] vs OpS 5 of 66 [8%]) did not differ 
between laparoscopic and open surgery groups.
Operative risk
 The distribution of ages and Cr-POSSUM were 
showed in Table 1. 37 patients (56%) in OpS group were 
with a Cr-POSSUM score ≥10%, 13 patients (20% in 
total) of which were with a Cr-POSSUM score ≥20%; 
while in LapS group, the amount of patients with score 
above 10% and 20% were 30 patients (45%) and 15 
patients (22%), respectively. Concerning the 4 patients 
whose scores were below 5% in OpS group, three patients 
were older than 50 years old with pulmonary dysfunction, 
one patient was 59 years old undergoing re-do surgery. In 
LapS group, three in five patients were beyond 50 years 
old combining with pulmonary dysfunction; one was with 
chronic renal impairment; one patient experienced re-do 
surgery. In total, there were 3 and 2 patients in each group 
underwent re-do surgery, eighteen and twelve patients 
suffered from acute or chronic renal impairment, thirteen 
and eight patients were suffering from diabetes mellitus 
in OpS and LapS group, respectively. 50%, 50% patients 
in OpS group and 32%, 33% patients were suffering from 
Cardiac and respiratory disease, respectively. 3% patients 
in the open surgery group have cerebrovascular disease. 
Generally speaking, there was no significant difference 
between the two groups in preoperative risk. 
Postoperative complications and outcomes
 The postoperative complications included surgical 
complications as well as general complications. Surgical 
complications contain anastomotic leakage [11], ileus, 
intra-abdominal abscess, urological or perineal wound 
complications, fistula, hemorrhage and deep vein 
thrombosis (Table 2). And there were no significant 
differences between two groups except that laparoscopic 
group has a significant lower wound complication rate (2 
vs 9). General complications include cardiac, respiratory, 
neurological and renal complications, Ascites etc. Cardiac 
complications happened in 4 and 3 patients respectively 
in OpS and LapS groups, containing postoperative heart 
failure, arrhythmia, angina and ischemic heart diseases, 
while, the number of patients in the laparoscopic group 
with respiratory complications was significantly lower 
(p = 0.03). Notably, the total complication rate between 
conventional open rectal resection (71 %) and laparoscopic 
surgery (41%) showed a significant difference (p = 
0.0005). 2 cases (3%) in the LapS group were converted 
to open surgery in the present study. 
The correlation analysis of Cr-POSSUM and 
dindo-demartines-clavien classification
 There is no significant difference between 
laparoscopic surgery and conventional surgical 
procedure in the distribution of Dindo-Demartines-
Clavien Classification (p = 0.92). There is a significant 
Figure 1: 5-year overall survival rates of Different Tumor Stages. After Log-rank analysis, no difference could be found 
between patients undergoing laparoscopic and open rectal resection in stage I~II (p = 0.13, HR 0.5565, 95%CI 0.26-1.19, Figure1A), 
whereas the overall survival rate was statistically significantly higher in LapS group with stage III-IV tumor (p < 0.0001, HR 0.70, 95%CI 
0.27-1.79, Figure1B)
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positive correlation between open surgery and the Dindo-
Demartines-Clavien Classification (Estimate = 0.7495, 
p= 0.02, 95%CI 1.102~4.062). In addition, Cr-POSSUM 
is positively correlated with Dindo-Demartines-Clavien 
Classification (Estimate = 0.0458, p = 0.01, 95%CI 
1.010~1.085). 
5-year overall survival, disease-free survival and 
disease-specific survival rates of different tumor 
stages and Cr-POSSUM score sub-groups
 The median follow-up is 49.5 months. Using Log-
rank analysis, no difference could be found between 
patients undergoing laparoscopic and open rectal 
resection in stage I~II (p = 0.13, HR 0.5565, 95%CI 0.26-
1.19), whereas the overall survival rate was statistically 
significantly higher in LapS group with stage III-IV tumor 
(p < 0.0001, HR 0.70, 95%CI 0.27-1.79) Figure 1. We 
further used Cox regression to analyze the 132 patients; 
it also showed patients undergoing laparoscopic rectal 
resection had a better overall survival rate. 
The 5- year overall survival curves of patients 
in different Cr-POSSUM score sub-groups are shown 
in Figure 2D, 2E, 2F. The actuarial survivals of the 
laparoscopic and open groups with Cr-POSSUM valuing 
10~20% was without significantly different (p = 0.12, 
HR 2.02, 95%CI 0.83-4.90), so was for patients with 
Cr-POSSUM below 10% (p = 0.46) or above 20% (p = 
0.64). The 5-year disease-free survival and disease specific 
survival are showed in Table 3.
Overall survival, disease-free survival and 
disease-specific survival rates of patients with 
preoperative cardiac, renal or respiratory diseases
 The overall survival rates of patients with 
cardiovascular, pulmonary and renal diseases are shown 
in Figure 2A, 2B, 2C. In patients with the preoperative 
pulmonary disease, the 5-year overall survival rates of all 
stages and every different stage in these two groups were 
significantly different (p = 0.03 [OS], p = 0.02 [DFS]), 
while in patients with cardiovascular disease, the 5-year 
overall survivals were not significantly different (p = 0.9). 
For patients with the preoperative renal disease, the 5-year 
overall survival rates benefit from laparoscopic surgery 
with a significant difference. (p = 0.049), however, the 
disease-specific survival was not significantly different. 
Furthermore, although people older than 75 years 
account for only 5~10% of the overall population in 
developed countries and some developing countries, 
35~45% of patients with rectal cancer are in this age 
group. This proportion may increase in the future because 
Figure 2: Overall survival rates of patients with preoperative diseases or patients in different Cr-POSSUM score sub-
groups. A.-C., the overall survival rates of patients with cardiovascular, pulmonary and renal diseases. D.- F., The 5- year survival curves 
of patients in different Cr-POSSUM score sub-groups.
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Table 3: Disease free survival, disease specific survival and overall survival 
Subgroup 5-year survival HR(95%CI) p
Stage I~II
Disease free survival LapS 76.7% 0.58(0.28~1.19) 0.14
OpS 89.1%
Disease specific survival LapS 74.1% 0.63(0.29~1.36) 0.24
OpS 88.6%
Stage III~IV
Disease free survival LapS 60% 5.14(2.27~11.68) <0.0001
OpS 38.4%
Disease specific survival LapS 62.1% 5.57(2.42~12.81) <0.0001
OpS 38.4%
Preoperative respiratory 
disease
Disease free survival LapS 82.5% 0.40(0.18~0.87) 0.02
OpS 64.6%
Disease specific survival LapS 86.4% 0.45(.020~1.04) 0.047
OpS 73.3%
Preoperative renal disease
Disease free survival LapS 80.9% 0.41(0.15~1.12) 0.049
OpS 59.9%
Disease specific survival LapS 81.9% 0.38(0.13~1.15) 0.06
OpS 61.6%
Preoperative cardiac disease
Disease free survival LapS 71.9% 0.98(0.41~2.37) 0.98
OpS 75.6%
Disease specific survival LapS 75.2% 0.81(0.32~2.09) 0.68
OpS 76.9%
Cr-POSSUM<10
Disease free survival LapS 84.2% 0.68(0.27~1.70) 0.40
OpS 89.1%
Disease specific survival LapS 84.2% 2.34(1.08~5.07) 0.43
OpS 82.9%
Cr-POSSUM 10~20
Disease free survival LapS 73.8% 1.39(0.48~4.01) 0.54
OpS 66.5%
Disease specific survival LapS 73.8% 1.28(0.43~3.78) 0.66
OpS 68.8%
Cr-POSSUM >20
Disease free survival LapS 63.6% 1.44(0.54~3.82) 0.46
OpS 61.1%
Disease specific survival LapS 72.5% 2.49(0.81~7.64) 0.11
OpS 57.6%
>75
Disease free survival LapS 64.4% 0.89(0.42~1.89) 0.76
OpS 60.7%
Disease specific survival LapS 69.4% 0.66(0.29~1.42) 0.32
OpS 59.1%
<75
Disease free survival LapS 62.9% 0.79(0.36~1.72) 0.55
OpS 60.8%
Disease specific survival LapS 62.9% 0.79(0.36~1.72) 0.55
OpS 60.8%
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of demographics of an aging population, and increases in 
life expectancy [12]. Thus, we separated the patients into 
two sub-groups (~75, > 75) by age (LapS 23 of 66 [35%] 
> 75y, OpS 26 of 66 [39%] > 75y). The overall survival 
rate (Figure 3), disease-free survival rate, disease specific 
survival rate and the complication rate (not show) did not 
differ significantly in each group.
DISCUSSION
Recently, the continual innovations of surgical 
approach are a major step towards the idea of personalized 
medicine, we should notice that it is still controversial 
about the treatment strategy for elderly patients with rectal 
tumor and those with elevated operative risk. Especially 
for patients with elevated operative risk, patients are most 
vulnerable when their pre-existing comorbidities make 
them susceptible to perioperative risk [13, 14, 15]. 
The COREAN trial demonstrated similar 
disease-free survival (Lap79.2% vs Open 72.5%) and 
overall survival rates (Lap 91.7% vs Open 90.4%). 
The 3-year disease-free survival rate (Lap74.8% vs 
Open 70.8%) and overall survival rates were similar 
between both approaches in COLOR II trial as well. 
More recently, American College of Surgeons Oncology 
Group [ACOSOG] Z6051 trial [16] and Australasian 
Laparoscopic Cancer of the Rectum Randomized Clinical 
Trial [AlaCaRT] [17] investigated the non-inferiority of 
minimally invasive compared with open pelvic dissection 
for rectal cancer patients. The results suggest that a 
laparoscopic resection may not be oncologically justified 
in many patients requiring protectomy for rectal cancer. 
However, it was also reported that the follow-up studies 
to the ACOSOG Z6051 and ALaCaRT trials may show 
that long-term oncologic outcome are not compromised by 
a laparoscopic approach and slightly favorable outcomes 
might be seen as demonstrated by the COREAN and 
COLOR II trials. Other randomized trials and systematic 
reviews have also reported that laparoscopic and open 
proctectomy have similar oncological outcomes [18].
However, little solid evidence exists in support of 
laparoscopic or open proctectomy for patients with high 
operative risk, although some literature showed that 
perioperative morbidity did not differ between two groups 
(Table 4). 
It is well accepted that laparoscopic approach is 
equivalent in the treatment of rectal cancer and shows 
advantages of shorter hospitalization and faster recovery, 
lower blood loss and lower complications rates [19], 
especially in patients with low rectal cancer [20, 21, 22]. 
Pulmonary comorbidities have been considered 
as an independent predictor of poor outcome in patients 
undergoing colectomy and appear to be enhanced in 
patients with chronic renal diseases. Chronic kidney 
diseases require dialysis is also a known surgical risk 
factor that in bowel resection increases the risk of 
death nearly 6-fold and doubles the complication rate. 
Therefore, some literature suggests laparoscopic surgery 
is not attempted for these patients considering their 
body habitus or longer operative time or creation of 
pneumoperitoneum which may be potentially associated 
with adverse pathophysiological changes, including 
hypercapnia, reduced venous return. However, in this 
study, patients with preoperative respiratory diseases and 
Figure 3: The overall survival rates in age sub-groups (~75, > 75). 
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Table 4: Recent comparative series in advanced rectal cancer 
Reference Year Lap: Open Follow up Stage Survival P value 
Park et al 2009 170:374 36m (2-75) 1-3 3-year  DFS     lap 77.5% 0.29
                          Open 82.6%
Laurent et al 2009 238:233 52m(1-151) 1-3 5-year  DFS     lap 82% NS
                         Open 79%
3 5-year  DFS     lap ~69% NS
                          Open ~69%
3 5-year  OS      lap ~72% 0.02
                        Open ~52%
Law et al 2009 111:310 34m 3 5-year   OS     lap 56.6% 0.33
                        Open 50%
Li et al 2011 113:123 74.8m 3 5-year   OS     lap 66.7% 0.85
                        Open 70.3%
1-3 5-year   OS     lap 77.9% 0.91
                        Open 78.9%
Liang et al 2011 69:174 Until 3 year 1-3 3-year   OS     NS
Baik et al 2011 54:108 Until 5 year 3 5-year   OS     lap 91.7% 0.30
                        Open 77.2%
3 5-year   DFS   lap ~58.8% 0.63
                         Open ~51.5%
Law et al 2012 814:1197 40.3m 3 5-year  OS      lap ~58% 0.18
                         Open ~48%
Parket al 2013 404:404 Until 3 years 1-3 5-year   OS     lap 82.1% 0.44
                        Open 81.3%
3 5-year   OS     lap ~70% 0.26
                        Open ~73%
3 5-year   DFS   lap ~69% 0.18
                        Open ~59%
Asoglu et al 2013 513:0 31m(7-64) 3 5-year   OS     lap ~70% -
Good et al30 2013 130:0 40m 3 5-year   OS     lap 75.6% -
4 5-year   OS     lap 53.8% -
Ng SS et al 2014 136:142 Until 10 years 1-3 10-year  OS    lap ~58%
                         Open ~48%
3 10-year  RR     lap 25.8% 0.08
                         Open 43.2%
Reibetanz et al29 2014 170:170 48m vs 46m 1-3 3-year   OS     NS
Bonjer et al  
( COLORII ) 2015 699:345 Until 3 year 1-3
3-year  OS      lap    86.7%
                        Open 83.6%
              DFS   lap     74.8%
                        Open 70.8%
              RR     lap           5%                      
                        Open       5%
NS
NS
NS
Jeong et al
(COREAN) 2015 170:170 Until 3 year 1-4
3-year   OS     lap     91.7%
                        Open 90.4%
              DFS   lap     79.2%
                        Open 72.2%          
NS
NS
OS, overall survival; DFS, disease free survival; RR, recurrence rate
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renal diseases benefit from laparoscopic surgery, which 
was consistent with previous reports. The reasons might 
be lower pain rate, less complication rate in laparoscopic 
surgery, and also it might be attributable to the enhanced 
post-operative recovery of lung function in laparoscopic 
group [23, 24]. Besides, a lung-protective PEEP during 
pneumoperitoneum might be also valuable for preventing 
intratidal recruitment/derecruitment [25].
Presently, better preoperative risk assessment should 
be introduced, objective and accurate evaluation of risk 
should become routine procedures, those would be helpful 
to predict and avoid postoperative complications by 
selecting the appropriate surgical approach. Cr-POSSUM 
model is a promising specialized tool for monitoring 
surgical outcomes in colorectal cancer surgery, which 
might be more accurate than P-POSSUM score [26, 
27] in pre-operative use. In present research, patients 
suffering stage III/IV tumor with a laparoscopic surgery 
(60%) had primarily a significantly better outcome than 
patients undergoing open surgery (38.4%), as compared 
with DFS rates of 64.9% after laparoscopic surgery and 
52.0% after open surgery among patients with stage III 
disease in the COREAN study. There was no significant 
difference in different Cr-POSSUM subgroups. Other 
study findings showed that elder patients might benefit 
most from improved short-term postoperative outcomes 
following the laparoscopic surgery [28]. Our research 
did not indicate significant improvements in the overall 
survival in different age group. The comparable survival 
rates were reported in series of literature. But the present 
study showed superior survival in laparoscopic resection, 
especially in stage III/IV cancers. We reviewed recent 
researchers: in 2010, the UK MRC CLASICC trial 
demonstrated that the 5-year overall survival rate (OSR) 
was 60.3% for laparoscopic rectal resection versus 52.9% 
for open surgery. Feliciotti´s group [29] (62.5%vs 60.6%), 
Ng et al [30] (63.9 %vs 55%), Law´s group [31] (71.1%vs 
59.3%), Jayne et al [32] (60.3%vs 52.9%) and Baik et al 
[33] (90.8% vs 88.5%) all presented a better 5-year OSR 
for laparoscopic rectal resection, though the differences 
were not significant. Recently, it was reported that 
laparoscopic resection is associated with more favorable 
5-year OS in stage II and III cancer [34, 35]. These results 
were not influenced by postoperative chemotherapy, which 
was given similarly after both approaches, especially for 
stage III cancer. The lower complication rate associated 
with laparoscopic resection might contribute to the better 
OS, this reason is more pronounced in the patients with 
high preoperative risk [36, 37, 38, 39]. Given the increased 
mortality and morbidity, all efforts should be made to 
medically optimize these patients preoperatively. One of 
the limitations of this study is the sample number, though 
the estimated power was 0.8 (α = 5%). For an instant, only 
a few patients with diabetes or cerebrovascular diseases 
were involved in the analyses which still need to be 
further improved under larger sample amount. Although 
a randomized controlled trial should be conducted to 
confirm the findings of the present study, the authors 
believe that the present study is of value in proposing the 
future studies.
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Abstract
AIM: To compare the clinicopathological features of 
patients with non-schistosomal rectosigmoid cancer 
and schistosomal rectosigmoid cancer.
METHODS: All the patients with rectosigmoid carci-
noma who underwent laparoscopic radical surgical 
resection in the Shanghai Minimally Invasive Surgical 
Center at Ruijin Hospital affiliated to Shanghai Jiao-
Tong University between October 2009 and October 
2013 were included in this study. Twenty-six cases of 
colonic schistosomiasis diagnosed through colonoscopy 
and pathological examinations were collected. Sym-
ptoms, endoscopic findings and clinicopathological 
characteristics were evaluated retrospectively.
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RESULTS: There were no significant differences bet-
ween patients with and without schistosomiasis in 
gender, age, CEA, CA19-9, preoperative biopsy findings 
or postoperative pathology. Patients with rectosigmoid 
schistosomiasis had a significantly higher CA-125 level 
and a larger proportion of these patients were at an 
early tumor stage (P  = 0.003). Various morphological 
characteristics of schistosomiasis combined with 
rectosigmoid cancer could be found by colonoscopic 
examination: 46% were fungating mass polyps, 23% 
were congestive and ulcerative polyps, 23% were 
cauliflower-like masses, 8% were annular masses. 
Only 27% of the patients were diagnosed with rectal 
carcinoma preoperatively after the biopsy. Computed 
tomography (CT) scans showed thickened intestinal 
walls combined with linear and tram-track calcifications 
in 26 patients.
CONCLUSION: Rectosigmoid carcinoma combined 
with schistosomiasis is associated with higher CA-125 
values and early tumor stages. CA-125 and CT scans 
have a reasonable sensitivity for the accurate diagnosis.
Key words: Schistosomiasis; Rectosigmoid cancer; 
Colonoscopy; Biomarker; Diagnosis
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The association between schistosomiasis and 
colorectal malignancy has long been suggested in the 
literature. This study aimed to improve our understanding 
of the relationship between Schistosoma japonicum-
related enteropathy and rectosigmoid carcinoma, with a 
particular focus on laboratory examination, endoscopic 
findings and clinicopathological characteristics of recto-
sigmoid schistosomiasis.
Feng H, Lu AG, Zhao XW, Han DP, Zhao JK, Shi L, Schiergens 
TS, Lee SML, Zhang WP, Thasler WE. Comparison of non-
schistosomal rectosigmoid cancer and schistosomal rectosigmoid 
cancer. World J Gastroenterol 2015; 21(23): 7225-7232 
Available from: URL: http://www.wjgnet.com/1007-9327/full/
v21/i23/7225.htm  DOI: http://dx.doi.org/10.3748/wjg.v21.
i23.7225
INTRODUCTION
Human schistosomiasis is a prevalent parasitic disease 
caused by trematode flukes of the genus Schistosoma, 
of which Schistosoma mansoni, Schistosoma japonicum 
(S. japonicum) and Schistosoma haematobium are 
the three major species. By conservative estimates, 
at least 230 million people worldwide are infected with 
Schistosoma spp, and it is important to acknowledge that 
schistosomiasis is now becoming a cause for concern 
in Europe, especially in southern Europe, because of 
climate change as well as infected travelers who return 
from endemic areas[1]. A number of epidemiological 
data has suggested a close etiological relationship 
between colorectal cancer and schistosomiasis, 
especially S. japonica[2,3]. The microenvironmental 
changes and inflammation may form a causal link 
between schistosome chronic infection and colorectal 
carcinogenesis[4,5]. However, as the symptoms of 
colonic schistosomiasis are nonspecific and may mimic 
other gastrointestinal problems, this condition could be 
under diagnosed[6], and there is little relevant clinical 
data in the medical literature, mostly limited to case 
reports[7-9]. On the other hand, in some schistosoma-
endemic areas, colonic schistosomiasis can be correctly 
diagnosed while colorectal cancer may be missed, 
especially when CEA or CA19-9 levels are within the 
normal range.
Detailed knowledge about schistosomiasis is 
necessary to improve the accuracy of clinical diagnosis. 
At present, colorectal neoplasia associated with 
schistosoma has only been reported on few occasions.
This research was conducted retrospectively, based 
on the recent data of schistosomal rectosigmoid cancer, 
including surgical findings and clinicopathological 
characteristics, to find a sensitive biomarker that might 
improve the accuracy of clinical diagnosis, and discuss 
the probable etiological role of chronic schistosomal 
infestation in rectosigmoid cancer.
MATERIALS AND METHODS
Patient selection and diagnoses
In this study, retrospective analysis was conducted 
for 26 consecutive cases in patients diagnosed with 
rectosigmoid carcinoma combined with colonic schi-
stosomiasis between 01-10-2009 and 01-11-2013, 
who underwent surgical resection at the Shanghai 
Minimally Invasive Surgical Center of Ruijin Hospital, 
which is affiliated to Shanghai Jiao-Tong University. 
Those patients were admitted to hospital because 
of liquid or pasty diarrhea, abdominal pain, pain on 
colon palpation or hematochezia. Colonoscopies were 
performed in the outpatient service of our department 
1-14 d before hospitalization. Two to three biopsies 
were obtained and sent to the department of pathology. 
CT scans, magnetic resonance imaging and laboratory 
examinations were performed in the outpatient 
service or on the first day of hospitalization. Patients 
who were diagnosed with rectosigmoid carcinoma in 
the same time period without schistosomiasis were 
selected as a control group. After surgical resection, all 
specimens were reviewed histopathologically, and the 
pathological TNM stages were determined according 
to the classification established by the American Joint 
Committee on Cancer (AJCC, 7th edition). The gold 
standard for diagnosis of schistosomiasis depends 
on finding ova by microscopy in the colon, rectum or 
stool.
Table 1  Patient characteristics and colonoscopic findings  n (%) 
or mean ± SD
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Examination and data collection
Abdominal ultrasonography, laboratory profiles, urine 
and stool tests were acquired after being admitted to 
hospital. Data on clinicopathological characteristics and 
treatments were collected routinely from the hospital 
records by trained registrars.
Statistical analysis
Analyses were performed using Stat View 5.0 for 
Windows (SAS Institute Inc., Cary, NC, United States). 
The χ2 test or Fisher’s exact test were applied to analyze 
the categorical variables. The results were subjected to 
a nonparametric Mann-Whitney U test. A Student’s t-test 
was also used to analyze the intragroup differences. 
P < 0.05 was regarded as statistically significant. The 
statistical methods of this study were reviewed by Yi-
Fei Zhang from the Institute for Stroke and Dementia 
Research Hospital of the University of Munich.
RESULTS
Clinical characteristics
In this study, 26 patients were diagnosed with sigmoid 
or rectal carcinoma combined with rectosigmoid 
schistosomiasis. Of these patients, 69.2% were male, 
while 31% out of the patients were female. 12 patients 
(46%) had elevated CEA values (> 5 μg/mL) and 47% 
patients (7/15) had abnormal CA-125 values (> 35 
U/mL). The distribution of these biomarkers is shown 
in Figure 1. It worth noting that only 1 patient (9%, 
1/11) in this series had an abnormal CA19-9 value 
(> 37.0 U/mL). In addition, there were no significant 
differences in gender, age, CEA value, CA19-9 value 
or findings from preoperative biopsy when these 
two groups were compared, based on characteristics 
and colonoscopic findings. Instead, patients with 
rectosigmoid schistosomiasis had significantly higher 
CA-125 values than those without (P = 0.0001) 
(Table 1). 85% of the patients who were diagnosed 
with sigmoid or rectal carcinoma combined with 
rectosigmoid schistosomiasis were at early tumor 
stages (stage Ⅰ or stage Ⅱ), compared to 47% of 
patients without schistosomiasis (P = 0.003).
Endoscopic examination
Various morphological characteristics of schistosomiasis 
combined with rectosigmoid cancer were found in 
colonoscopic examinations (Figure 2). The fungating 
mass polyp was the major morphological type, being 
present in around 46% of all 26 patients. For the 
remaining patients, six (23%) had congestive and 
ulcerative polyps, six (23%) had cauliflower-like 
masses and two (8%) were annular type. Preoperative 
rectosigmoid biopsy provides an efficient but insensitive 
way of visualizing eggs, especially for those with low 
worm burdens. In this study, only seven patients 
(27%) were diagnosed with rectosigmoid carcinoma 
preoperatively; 19% of the biopsies showed hyperplastic 
polyps, and 8% and 23% revealed intraepithelial 
neoplastic changes (Table 1).
CT presentation
Abdominal CT enhanced dynamic scans (CTA) demon-
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Figure 1  Quantities of CEA, CA19-9 and CA125 in the peripheral 
blood of patients who had rectosigmoid carcinoma with or without 
schistosomiasis. Dotted lines define the normal values. RSC: Rectosigmoid 
carcinoma; Sch: Schistosomiasis.
With 
schistosomiasis
Without 
schistosomiasis
(n  = 26) (n  = 34) P  value
Gender male/female 18/8 22/12
Age (yr)   60.7 ± 10.6  63 ± 8.7 0.6100
CEA   4.2 ± 8.8   82.9 ± 428.1 0.3800
CA19-9     10.9 ± 306.5 35.1 ± 65.1 0.1300
CA-125 27.4 ± 3.3 12.7 ± 10.0 0.0001
Preoperative biopsy
   Carcinoma   7 (26.9)    16 (47.1)
   Hyperplastic polyps   5 (19.2)      8 (23.5)
   Villous adenoma   3 (11.5)    1 (2.9)
   Tubular adenoma   3 (11.5)    1 (2.9) 0.3400
   Others   8 (30.7)      8 (23.5)
Morphology
   Congestive, Ulcerative   6 (23.1)    13 (38.2)
   Fungating mass 12 (46.2)      8 (23.5) 0.1600
   Cauliflower-like mass   6 (23.1)      6 (17.6)
   Annular  2 (7.6)      7 (20.6)
Tumor stage
   Ⅰ 16 (61.5)      6 (17.6)
   Ⅱ   6 (23.1)    10 (29.4) 0.0030
   Ⅲ   4 (15.4) 17 (50)
   Ⅳ 0    1 (2.9)
Differentiation
   Well 16 (61.5)    15 (44.1)
   Moderate   7 (26.9)    16 (47.1) 0.4000
   Poor   3 (11.5)    3 (8.8)
Postoperative pathology
   Adenocarcinoma 16 (61.5)    30 (88.2)
   Signet-ring cell carcinoma 7 (7.7) 0 0.1300
   Mucinous adenocarcinoma   3 (30.8)      4 (11.8)
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strated evenly thickened intestinal walls combined with 
linear and tram-track calcifications in 26 patients, with 
(8%) or without (92%) perirectal fatty infiltration, 
the rectal lumen were locally narrowed in the 
primary lesions. Calcified ova could be found in 22 
patients (85%). No significant lymphadenopathy was 
demonstrated. For those who had intestinal stenosis 
and for whom colonoscopic examinations were not 
recommended, virtual colonoscopy and virtual dissection 
were used to assess the condition and situation (Figure 
3B-D).
Laparoscopic surgical finding and pathology characters
Irregular thickening of the intestinal wall was found in 
25 patients (96%) during operations or postoperative 
sample assessments. Most of the patients were at 
Stage Ⅰ (62%), and 23% and 15% were at Stage 
Ⅱ and Stage Ⅲ, respectively. In 18 patients (69%), 
schistosomal ova were only found in the submucosal 
layer; in 19% the ova had infiltrated muscularis 
propria, and serosal infiltrations were found in 12% 
of the patients. In 8% of the patients, schistosomal 
ova could be found infiltrating into the surrounding 
lymph nodes postoperatively. In 21 patients (81%), 
schistosomal ova could be found inside the tumor, 
while ova from the remaining 19% of patients were 
found in the adjacent tissues (Figure 4). Considering 
the pathological profiles, the largest percentage 
had well differentiated tumors and adenocarcinoma 
observed in postoperative pathological examination. 
The information on signet-ring cell carcinomas (8%) 
and mucinous adenocarcinomas (31%) were also 
included in the present study (Table 2).
DISCUSSION
Schistosomal rectal cancer: better or worse prognosis?
Although schistosomiasis has been controlled in endemic 
regions[10] in the tropics and subtropics, previous S. 
japonicum infection might lead to complications, such 
as chronic intestinal schistosomiasis and hepatosplenic 
schistosomiasis, and this condition is significantly 
associated with both liver cancer and colorectal cancer[11]. 
Schistosome infection may have a negative effect 
on the prognosis of colorectal cancer[12]; it has been 
reported that the five-year survival rate was 45.6% 
out of 430 cases complicated with schistosomiasis, 
which was significantly lower than in those without 
schistosomiasis (50.9% out of 2717)[13 ]. In the present 
study, schistosomal rectosigmoid cancer seemed to 
be related to early tumor stage, possibly because 
schistosomiasis-related intestinal damages are mainly 
granuloma and fibrosis resulting from schistosomal 
ova deposition, especially in the large intestine[14-16]. 
Continuous epithelial proliferation adjacent to a chronic 
schistosomal ulcer and polyp formation, which lead 
to more obvious symptoms, might encourage the 
patients to seek a medical examination earlier. Wang 
et al[17] analyzed 30 patients with schistosomal rectal 
cancer and showed that schistosomiasis (P = 0.026) 
A B
C D
Figure 2  Endoscopic findings showing different morphological characteristics of schistosomiasis combined with rectal cancer. A: Annular; B: Fungating 
mass; C: Cauliflower-like mass; D: Congestive, ulcerative (black arrow).
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Figure 3  Computed tomography presentation. A: Computed tomography (CT) scan showing curvilinear calcification in the rectosigmoid colon and calcified, 
conglomerate nodules (arrow) protruding from the wall of the rectosigmoid colon; B: Lobulated polypus in the rectum; C, D: CTVC enables three-dimensional view of 
walls of the colon as a result of reconstruction of multislice CT images. The colorectal stenosis is showed in the area surrounding by dotted lines. CTVC: CT virtual 
colonoscopy.
DC
BA
Figure 4  Pathological features of schistosomiasis-associated rectal adenocarcinoma. A, B: Schistosomiasis ova in tumor adjacent tissues. C, D: 
Schistosomiasis ova in tumor tissues.
A B
C D
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Table 2  Laparoscopic surgery findings and pathological 
characteristics  n  (%)
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was statistically significantly correlated with overall 
survival (OS). Schistosomiasis was an independent 
prognostic factor for worse DFS and OS in multivariate 
analysis[17].
Sensitivity of biomarker examinations
In cases of intestinal cancer associated with schisto-
somiasis, the location of the cancer was predominately 
the rectum[18], followed by the sigmoid colon, and then 
the other parts of the colon, while small intestinal 
cancer with a relatively lower distribution of S. 
japonicum eggs is quite rare[4,19]. Fan et al[20] analyzed 
285 pathological specimens with colorectal cancer 
from surgical operations in an endemic area for 
schistosomiasis and found that cancer in the rectum 
and sigmoid colon accounted for 44% and 27% in the 
220 cases of cancer combined with schistosomiasis, 
respectively. In those patients without schistosomiasis, 
the comparative figure was 23% and 18%, respectively, 
with a significant difference[20]. Peripheral blood tumor 
marker IL-2, TNF-2 and CEA might be elevated in 
those patients[21]. Yu et al[22] divided schistosomal egg 
induced polyps into three types: fibrous type, mixed 
type and epithelial proliferative type; CEA and PNA 
receptors were present in 18/20 (90%) and 6/18 of 
epithelial proliferative type, respectively. In the present 
study, 46% and 47% patients had elevated CEA or 
CA-125, whilst few patients had abnormal CA19-9. On 
the other hand, after statistical analysis, schistosomal 
rectosigmoid carcinoma was only associated with a 
higher CA-125 level.
Is colonoscopy specific?
Colonoscopy provides valuable information for the 
diagnosis of colonic schistosomiasis[23]. Liu et al[3] 
systematically described morphological types of 
schistosomal colorectal cancer (endophytic/ulcerative, 
exophytic/fungating, annular, giant polyp and IIc), and 
found that the ulcerative type were the most common 
cases. However, in this study, which focused on 
rectosigmoid cancers, fungating masses seemed form 
the majority of the cases. The endoscopic findings of 
schistosomal rectosigmoid cancer were non-specific.
Considering the diagnoses of carcinoma, only 27% 
of the patients were diagnosed with rectal carcinomas 
preoperatively, 19% of the biopsies showed hyperplastic 
polyps, and 8% and 23% revealed low or high grade 
intraepithelial neoplastic changes, respectively. 
Considering the diagnosis of colonic schistosomiasis: if 
schistosoma ova are not observed in biopsies, the near-
normal crypts with excess mucus and diffuse or focal 
infiltration of eosinophilic granulocytes may be highly 
suggestive of colonic schistosomiasis[24]. Therefore, 
multisite biopsies are recommended to improve the 
accuracy of diagnosis. Ye et al[25] analyzed clinical and 
endoscopic manifestations for 96 patients, and found 
that epidemiological investigations and colonoscopic 
examinations combined with multi-block and multi-site 
biopsies may improve the rate of correct diagnosis of 
intestinal schistosomiasis.
Recent technological advances have significantly 
enhanced the role of imaging in the detection, charac-
terization, and management of infectious diseases 
involving the large intestine. Lee et al[26] reported that 
CT demonstrated calcifications resembling tram tracks 
in the sigmoid colon and postulated that the tram-track 
appearance is noted only in the distal large intestine 
because this portion of the colon has a thicker, 
muscular layer than the proximal colon. Irregular 
thickening of the intestinal wall, soft tissue masses, 
multiple S. japonicum ova calcifications inside the 
tumor with obscured margins and multiple intestinal 
masses in some patients, are important CT features 
of CRC with schistosomiasis. Zhang et al[27] compared 
the CT presentation and pathological characteristics 
and found that the intestinal wall was irregularly 
thickened in 95% of the patients, with soft tissue 
masses in 5% patients. Linear, spotty and small patchy 
calcifications were seen in 104 (80%) patients, with 
96 out of 130 patients having ill-defined margins[27]. 
In support of this view, in our study, CT scan and CT 
virtual colonography have a reasonable sensitivity 
and specificity for detecting these lesions. CT allowed 
the visualization of evenly thickened intestinal wall 
combined with linear and tram-track calcifications in all 
26 patients.
Recent studies have also thrown some light on 
the molecular events associated with schistosomal 
colorectal cancer. Ruan et al[28] found that the 
expressions of vascular growth factors including PD-
ECGF and VEGF are higher in the colorectal carcinoma 
patients with schistosomiasis than in those without. 
Zalata et al[29] found that signet ring cell carcinoma 
and mucinous adenocarcinoma both exhibited intense 
c-myc expression compared with non-mucinous 
carcinoma (P = 0.001). When adjusting for S. mansoni 
infection, 58% of schistosomal colorectal cancer cases 
were Bcl-2 positive compared with only 33% of non-
schistosomal colorectal cancers (P = 0.046). They 
also suggested that the genotoxic agents produced 
Male, n Female, n Total
Schistosomal ova position
   Submucosa infiltration 12 6 18 (69.2)
   Muscularis propria   4 1   5 (19.2)
   Serosal infiltration   2 1   3 (11.5)
Infiltration in the sLNs   1 1 2
Intra-tumor tissue 14 7 21 (80.8)
Para-tumor tissue   4 1   5 (19.2)
Calcification ova (CT) 15 7 22 (84.6)
Irregular thickening of the intestinal wall 17 8 25 (96.2)
Rough serosal surface   2 1   3 (11.5)
CT: Computed tomography; sLNs: Surrounding lymph nodes.
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endogenously through the course of Schistosomiasis 
mansoni infection may play a role in CRC- Schistosoma 
mansoni pathogenesis through the dysregulation of 
apoptosis by the alteration of the expression pattern of 
Bcl-2 protein[29].
A recent study showed that the prognosis of 
patients with schistosomal rectal cancer is worse than 
those with non-schistosomal rectal cancer; therefore, 
a diagnosis of schistosomiasis might be necessary[17]. 
In the present research, CA-125 levels and CT scans 
have a sufficient sensitivity to diagnose rectosigmoid 
carcinoma combined with schistosomiasis.
COMMENTS
Background
Colorectal cancer coexisting with schistosomiasis is a typical schistosomiasis-
related intestinal damage, especially in the sigmoid colon and rectum.
Research frontiers
Epidemiological data have suggested that a close relationship exists 
between colorectal cancer and schistosomiasis, especially when infected 
with Schistosoma japonicum. However, there have been little available data 
regarding the role of Schistosoma japonicum in rectosigmoid carcinoma.
Innovations and breakthroughs
The authors compared the clinicopathological features of patients with non-
schistosomal rectosigmoid cancer or schistosomal rectosigmoid cancer, 
and analyzed the laboratory examinations, endoscopic findings and 
clinicopathological characteristics between those two groups. There were 
no significant differences in CEA values, CA19-9 values or findings from 
preoperative biopsies. However, patients with rectosigmoid schistosomiasis had 
significantly higher CA-125 values.
Applications
According to this study, rectosigmoid carcinoma combined with schistosomiasis 
might be associated with higher CA-125 values and early stages; CA-125 and 
computed tomography (CT) scans have a sufficient sensitivity for accurate 
diagnosis.
Terminology
Endoscopy and CT scans contribute to the diagnosis of schistosomal 
rectosigmoid carcinoma, although they are nonspecific. A correct diagnosis 
of schistosomal rectosigmoid carcinoma can be established by endoscopy as 
well as CT scans in combination with its clinicopathological characteristics and 
laboratory tests (CA-125).
Peer-review
The manuscript written by Feng et al retrospectively evaluated the 
endoscopic findings and clinicopathological characteristics of schistosomal 
rectosigmoid cancer. The findings are important and provide novel information 
for the management of patients with rectosigmoid carcinoma, as well as 
schistosomiasis. However, there are some concerns that need to be addressed.
REFERENCES
1 Colley DG , Bustinduy AL, Secor WE, King CH. Human 
schistosomiasis. Lancet 2014; 383: 2253-2264 [PMID: 24698483 
DOI: 10.1016/S0140-6736(13)61949-2]
2 Chen MG . Assessment of morbidity due to Schistosoma 
japonicum infection in China. Infect Dis Poverty 2014; 3: 6 [PMID: 
24529186 DOI: 10.1186/2049-9957-3-6]
3 Liu W, Zeng HZ, Wang QM, Yi H, Mou Y, Wu CC, Hu B, Tang 
CW. Schistosomiasis combined with colorectal carcinoma diagnosed 
based on endoscopic findings and clinicopathological characteristics: 
a report on 32 cases. Asian Pac J Cancer Prev 2013; 14: 4839-4842 
[PMID: 24083755 DOI: 10.7314/APJCP.2013.14.8.4839]
4 Steinmann P , Keiser J , Bos R, Tanner M, Utzinger J . 
Schistosomiasis and water resources development: systematic 
review, meta-analysis, and estimates of people at risk. Lancet 
Infect Dis 2006; 6: 411-425 [PMID: 16790382 DOI: 10.1016/
S1473-3099(06)70521-7]
5 Konishi T, Watanabe T, Shibahara J, Nagawa H. Surveillance 
colonoscopy should be conducted in patients with colorectal 
Shistosomiasis even after successful treatment of the disease. Int J 
Immunopathol Pharmacol 2006; 19: 245-246 [PMID: 16569365]
6 Mohamed AR, al Karawi M, Yasawy MI. Schistosomal colonic 
disease. Gut 1990; 31: 439-442 [PMID: 2110925 DOI: 10.1136/
gut.31.4.439]
7 Botes SN, Ibirogba SB, McCallum AD, Kahn D. Schistosoma 
prevalence in appendicitis. World J Surg 2015; 39: 1080-1083 
[PMID: 25609120 DOI: 10.1007/s00268-015-2954-3]
8 Li WC, Pan ZG, Sun YH. Sigmoid colonic carcinoma associated 
with deposited ova of Schistosoma japonicum: a case report. World 
J Gastroenterol 2006; 12: 6077-6079 [PMID: 17009414 DOI: 
10.3748/wjg.v12.i37.6077]
9 Issa I, Osman M, Aftimos G. Schistosomiasis manifesting as a 
colon polyp: a case report. J Med Case Rep 2014; 8: 331 [PMID: 
25296942 DOI: 10.1186/1752-1947-8-331]
10 Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. 
Lancet 2006; 368: 1106-1118 [PMID: 16997665 DOI: 10.1016/
S0140-6736(06)69440-3]
11 Gray DJ , Ross AG, Li YS, McManus DP. Diagnosis and 
management of schistosomiasis. BMJ 2011; 342: d2651 [PMID: 
21586478 DOI: 10.1136/bmj.d2651]
12 Chen MC, Chang PY, Chuang CY, Chen YJ, Wang FP, Tang YC, 
Chou SC. Colorectal cancer and schistosomiasis. Lancet 1981; 1: 
971-973 [PMID: 6112388]
13 Schistosomiasis and its prognostic significance in patients with 
colorectal cancer. National Cooperative Group on Pathology and 
Prognosis of Colorectal Cancer. Zhonghua Zhongliu Zazhi 1986; 8: 
149-151 [PMID: 3021419]
14 Madbouly KM, Senagore AJ, Mukerjee A, Hussien AM, Shehata 
MA, Navine P, Delaney CP, Fazio VW. Colorectal cancer in a 
population with endemic Schistosoma mansoni: is this an at-
risk population? Int J Colorectal Dis 2007; 22: 175-181 [PMID: 
16786317 DOI: 10.1007/s00384-006-0144-3]
15 Singh KP, Gerard HC, Hudson AP, Boros DL. Differential 
expression of collagen, MMP, TIMP and fibrogenic-cytokine genes 
in the granulomatous colon of Schistosoma mansoni-infected mice. 
Ann Trop Med Parasitol 2006; 100: 611-620 [PMID: 16989687 
DOI: 10.1179/136485906X118530]
16 Chen Y, Boros DL. Polarization of the immune response to the 
single immunodominant epitope of p38, a major Schistosoma 
mansoni egg antigen, generates Th1- or Th2-type cytokines 
and granulomas. Infect Immun 1999; 67: 4570-4577 [PMID: 
10456902]
17 Wang M, Zhang YC, Yang XY, Wang ZQ. Prognostic analysis 
of schistosomal rectal cancer. Asian Pac J Cancer Prev 2014; 15: 
9271-9275 [PMID: 25422211 DOI: 10.7314/APJCP.2014.15.21.9271]
18 Schistosomes, liver flukes and Helicobacter pylori. IARC Working 
Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 
7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 
61: 1-241 [PMID: 7715068]
19 Hao WG, Wang XM, Yi WQ, Gao YP. [Analysis of lesions in 
498 schistosomiasis patients]. Zhongguo Xuexichongbing Fangzhi 
Zazhi 2013; 25: 428, 432 [PMID: 24358761]
20 Fan XL, Cheng HJ. Discussion on the relationship between 
schistosomiasis and colorectal cancer – histopathological analysis 
of 285 cases. Zhongguo Xuexichongbing Fangzhi Zazhi 1992; 3: 62
21 Hamed MA, Ahmed SA, Khaled HM. Efficiency of diagnostic 
biomarkers among colonic schistosomiasis Egyptian patients. Mem 
Inst Oswaldo Cruz 2011; 106: 322-329 [PMID: 21655820 DOI: 
10.1590/S0074-02762011000300011]
22 Yu XR, Chen PH, Xu JY, Xiao S, Shan ZJ, Zhu SJ. Histological 
classification of schistosomal egg induced polyps of colon and 
their clinical significance. An analysis of 272 cases. Chin Med J 
(Engl) 1991; 104: 64-70 [PMID: 1908760]
23 Cao J, Liu WJ, Xu XY, Zou XP. Endoscopic findings and 
clinicopathologic characteristics of colonic schistosomiasis: a 
 COMMENTS
Feng H et al . Colorectal carcinoma associated with schistosomiasis
7232 June 21, 2015|Volume 21|Issue 23|WJG|www.wjgnet.com
report of 46 cases. World J Gastroenterol 2010; 16: 723-727 [PMID: 
20135720 DOI: 10.3748/wjg.v16.i6.723]
24 Yosry A. Schistosomiasis and neoplasia. Contrib Microbiol 2006; 
13: 81-100 [PMID: 16627960 DOI: 10.1159/000092967]
25 Ye C, Tan S, Jiang L, Li M, Sun P, Shen L, Luo H. Endoscopic 
characteristics and causes of misdiagnosis of intestinal 
schistosomiasis. Mol Med Rep 2013; 8: 1089-1093 [PMID: 
23969514 DOI: 10.3892/mmr.2013.1648]
26 Lee RC, Chiang JH, Chou YH, Rubesin SE, Wu HP, Jeng WC, 
Hsu CC, Tiu CM, Chang T. Intestinal schistosomiasis japonica: 
CT-pathologic correlation. Radiology 1994; 193: 539-542 [PMID: 
7972775 DOI: 10.1148/radiology.193.2.7972775]
27 Zhang W, Wang PJ, Shen X, Wang GL, Zhao XH, Seema SF, 
Zheng SQ, Li MH. CT presentations of colorectal cancer with 
chronic schistosomiasis: A comparative study with pathological 
findings. Eur J Radiol 2012; 81: e835-e843 [PMID: 22658847 
DOI: 10.1016/j.ejrad.2012.02.020]
28 Ruan SL, Wang B, Lu QM, Dong LR, Cao CX, Xu SL, Shen 
WY. [Expression of vascular growth factors in intestinal tissues 
in colorectal carcinoma patients with schistosomiasis japonica]. 
Zhongguo Xuexichongbing Fangzhi Zazhi 2013; 25: 250-254 
[PMID: 24024441]
29 Zalata KR, Nasif WA, Ming SC, Lotfy M, Nada NA, El-Hak 
NG, Leech SH. p53, Bcl-2 and C-Myc expressions in colorectal 
carcinoma associated with schistosomiasis in Egypt. Cell Oncol 
2005; 27: 245-253 [PMID: 16308474]
P- Reviewer: Correa P, Mura B, Wexner SD 
S- Editor: Qi Y    L- Editor: Stewart G    E- Editor: Liu XM
Feng H et al . Colorectal carcinoma associated with schistosomiasis

Bone marrow-derived mesenchymal stromal
cells promote colorectal cancer cell death
under low-dose irradiation
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Background: Radiotherapy remains one of the cornerstones to improve the outcome of colorectal cancer (CRC)
patients. Radiotherapy of the CRC not only help to destroy cancer cells but also remodel the tumour microenvironment
by enhancing tumour-specific tropism of bone marrow-derived mesenchymal stromal cell (BM-MSC) from the peripheral
circulation. However, the role of local MSCs and recruited BM-MSC under radiation were not well defined. Indeed, the
functions of BM-MSC without irradiation intervention remained controversial in tumour progression: BM-MSC was
previously shown to modulate the immune function of major immune cells, resulting in an impaired immunological sensitivity
and to induce an increased risk of tumour recurrence. In contrast, it could also secrete various cytokines and possess anticancer
effect.
Methods: Three co-cultivation modules, 3D culture modules, and cancer organoids were established. The induction of cytokines
secretion in hBM-MSCs after irradiation was analysed by ELISA array and flow cytometry. AutoMac separator was used to separate
hBM-MSC and CRC automatically. Cells from the co-cultured group and the control group were then irradiated by UV-C lamp and
X-ray. Proliferation assay and viability assay were performed.
Results: In this study, we show that BM-MSCs can induce the EMT progression of CRC cells in vitro. When irradiated with low
doses of ultraviolet radiation and X-rays, BM-MSCs show an anti-tumour effect by secreting certain cytokine (TNF-a, IFN-g) that
lead to the inhibition of proliferation and induction of apoptosis of CRC cells. This was further verified in a 3D culture model of a
CRC cell in vitro. Furthermore, irradiation on the co-culture system induced the cleavage of caspase3, and attenuated the
phosphorylation of phosphatidylinositol 3-kinase (PI3K)/AKT and extracellular signal-regulated kinase in cancer cells. The signal
pathways above might contribute to the cancer cell death.
Conclusions: Taken together, we show that BM-MSC can potentially promote the effect of radiotherapy in CRC.
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Colorectal cancer (CRC) remains one of the most common
cancers worldwide, with B746 000 and 614 000 new diagnosed
cases per year in men and women, respectively (Schreuders et al,
2015). Despite rapid advances in multiple therapy strategies of
cancer, the efficacy of current treatment strategies is still far from
expected.
Mesenchymal stromal cells (MSCs) are a heterogeneous
group of progenitor cells that are important for tissue regeneration.
Cancer is considered as ‘wounds that never heal’ and thus MSCs,
in response to chemokine, are continuously recruited
and integrated into the tumour microenvironment. MSCs
within tumour microenvironment could exert both pro-apoptotic
and pro-survival effects on tumours and modulate the
immune functions by altering the cytokine secretion profile
of antigen presenting cells, T cells, and natural killer cells. It has
been proven that MSCs could secrete various cytokines and
possess anticancer effects (Pommey and Galipeau, 2006;
Hendijani and Javanmard, 2015; Liotta et al, 2015). However, on
the other hand, evidence was provided that MSC could also induce
an inflammatory and immune suppression microenvironment,
resulting in an impaired immunological sensitivity and the
promotion of tumour growth, which gives rise to an increased
risk of tumour recurrence (Houthuijzen et al, 2012; Chen et al,
2015).
In radiation oncology, classical viewpoints insist ionising
radiation works by penetrating and damaging the DNA
of cancerous tissue, which leads to cellular death. However,
the complex interaction between the cancer cell and stromal
cells, especially the function of MSCs under radiation, are
not very much investigated. Owing to the complexity of
interactions of different cell types within the tumour microenvir-
onment, we speculated that the components of tumour
microenvironment could also affect the systemic anti-cancer
effect of radiotherapy. At present, researchers used heterogeneous
culture of marrow stromal cells and claim they are MSCs.
Actually, MSCs contain several sub-populations: stromal cells,
progenitor cells, fibroblasts, and stem cells. In the present study,
the authors used MSCs containing a subpopulation of stem
cells (Galderisi and Giordano, 2014). Considering multipotency
and tumour tropism of MSCs, we further supposed that MSCs
could either sensitive or blunt the radiotherapy effect in CRC.
Growing evidence has shown that low doses of radiation also have
profound effects on cellular functions. Concerning stem cells,
owing to their longer lifespan, they could sustain more rounds of
lower doses of radiation, which may severely affect cellular
function but not cellular physiology (Fazel et al, 2009). In addition,
low doses of radiation could have already induced a reduction in
cycling MSCs and an increase in apoptotic cells, and these
proportions did not grow progressively as the doses increased
(Alessio et al, 2015).
To verify this hypothesis, we investigated the radiotherapy
sensitivity of CRC cell and bone marrow-derived mesenchymal
stromal cell (BM-MSC) under radiation in vitro. Our finding
suggests that: (1) MSCs can induce the mesenchymal phenotype of
CRC in vitro; (2) BM-MSCs under low-dose radiation show an
anti-tumour effect in 2D and 3D co-cultivation models by secreting
certain cytokine (TNF-a, IFN-g). (3) Irradiation on the co-culture
system induced the cleavage of caspase3, and attenuated the
phosphorylation of phosphatidylinositol 3-kinase (PI3K)/AKT and
extracellular signal-regulated kinase (ERK) in cancer cells. PI3K-
Akt signalling pathway is a signal transduction pathway that
promotes survival and growth in response to extracellular signals.
The suppression of this signalling pathway might lead to cancer
cell death. Therefore, the combination of administration of MSC
with radiotherapy might improve the outcome of CRC patients.
This study provides clues for an improved therapy alternative to
sensitise radiotherapy in CRC patients.
MATERIALS AND METHODS
Cell lines. Human CRC cell lines (HT-29, SW1116, and SW620)
were obtained from Shanghai Digestive Surgery Key Lab, which
was purchased and generated from American Type Culture
Collection (Manassas, VA, USA). CRC cells were cultured in
RPMI 1640 medium with GlutaMAX (GIBCO) supplemented with
10% fetal bovine serum (FBS) and penicillin–streptomycin
(100Uml 1 penicillin,100 mgml 1 streptomycin). Cells were
maintained at 37 1C in a 5% CO2 incubator (Thermo Fisher
Scientific, Darmstadt, Germany) according to standard protocols.
Pancreatic cancer BxPC3 and DanG cell lines were cultured in
GIBCO Dulbecco’s Modified Eagle Medium (DMEM, Thermo
Fisher Scientific). The medium was replaced routinely every 2–3
days. When 70–80% cell confluence has reached, the cells were
sub-cultured. Poietics Normal Human Bone Marrow-Derived
Mesenchymal stromal cells were complimentary from Group of
Dr med Tobias Schiergens, which were purchased from Lonza
(Walkersville, MD, USA) (Mayer–Wagner et al, 2011). MSC was
cultured in StemMACS MSC Expansion Media (130-091-680,
Miltenyi Biotec, Bergisch Gladbach, Germany) supplemented with
human StemMACS MSC Expansion Media Kit XF (Miltenyi
Biotec), 10% FBS (VWR Life Science, Visalia, CA, USA) and
penicillin–streptomycin. Fibroblast was isolated from cancer
specimens of CRC patients. The project was approved by the
Research Ethics Boards of Ruijin Hospital affiliated to Shanghai
Jiao Tong University and the informed consent was signed by the
patients.
Cell counting. The growth medium was discarded from the
culture dish (Corning, Inc., Christiansburg, VA, USA) and the
remaining adherent cells were collected by trypsinisation. Cells
were then counted with the CASY TT Cell Counter (Roche
Diagnostics, Indianapolis, IN, USA). Viable cells were discrimi-
nated from dead/apoptotic cells by trypan blue exclusion.
UV and ionising irradiation. Cells were seeded at a density of
2.5 103 cells cm 2 in 12-well plates. On the next day, Cells were
irradiated with a 254 nm UV-C lamp (UVP Inc., Upland, CA,
USA) at a dose of 10 Jm 2, which was measured with a UVX
radiometer. Irradiated cells were allowed to grow for 48B72 h
without changing the medium, according to a previously published
protocol, the dose has also been indicated in this publication (Lu
et al, 2012). Supernatant and the adherent cells growing on the dish
were collected, respectively. Viable adherent cells were counted.
For X-rays irradiation, cells were irradiated with an RS225 X-Ray
irradiator (200 kV, 10mA, 1Gy per 66 s) with the total dose of
10Gy. After irradiation, cells were returned to the incubator and
incubated for 24–48 h. The dose of the ultraviolet radiation and
ionising radiation used in this manuscript has been indicated in
other publications (Brozyna et al, 2007; Gullo et al, 2008; Deacon
et al, 2008; Sato et al, 2014; Fujita et al, 2015). The optimal
condition has also been confirmed by our preliminary experiment.
The co-culture model. To investigate the interaction of CRC cells
with MSCs, we used three different co-culture models: the wedge-
gap dish (Figure 1D), m–Slide 2 9 well (ibidi, Munich, Germany,
Figure 2F), and ibidi culture insert m–dish (ibidi, Supplementary
Figure 1C). For 2 9 well m–Slide, 50 ml CRC cells were seeded in
the centre minor well and 50 ml MSCs in each surrounding well at a
density of 2.5 103 cells cm 2. After cell attachment, 500 ml
RPMI1640 complete growth medium was added to the whole
growth area, allowing the cells in different nine wells to share
common growth medium under irradiation. For wedge-gap dishes
(Figure 1D), 2ml suspended CRC cells and 4ml suspended MSCs
were seeded in the inner dish and outer dish, respectively (MSC
was seeded 12 h later after the attachment of CRC cells), with the
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density of 2.5 103 cells cm 2. Similarly, 15ml RPMI1640
complete growth medium was added into dishes after cell
attachment, allowing inner and outer cells to share growth
medium. Cells were then treated with irradiation for 24–48 h.
Wound-healing assay of MSC and CRC cell. Wound-healing
assay of ‘two different cell line’ was performed to investigate the
interactions of different cell types. For this purpose, MSCs and
CRC cells (2.5 103 cells cm 2) were seeded into each well in
ibidi’s m-Dish35mm,high (ibidi), respectively. (Supplementary
Figure 1B). The insert was removed after cell attachment and
3ml RPMI 1640 complete growth medium was added to the
culture dish. For the control group, both wells in the insert were
seeded with the same cell line (either CRC cells or MSCs).
Subsequently, the co-culture system was treated with irradiation of
10 J cm 2 for 96 h, with irradiation untreated cells as the control
group.
Cell proliferation assay and colony formation assay. For cell
proliferation assay (Figure 3A), 4 104 SW1116 or HT29 cells
were seeded with or without (the control group) 1 104 MSCs in
12-well plate. The cells were then treated with 10 J cm 2
irradiation for 1 h per 6 h. Total cells in each well were counted
at 12 h, 36 h, and 72 h, respectively.
Similarly, in Figure 3C and D, CRC cells and MSCs was mixed
and seeded in ultra-low attachment 24-well plates with a different
ratio (CRC: MSCs, 25:25, 50:25, 100:25, 200:25). The same number
of CRCs seeded without MSCs in the plate was used as the control
group. Different amounts of CRC cells (50, 75, 125, and 225),
which were seeded in the plate, respectively, was used as the blank
control. Cells were then treated with 10 J cm 2 irradiation for 1 h
per 8 h, lasting for 8 days. Cell colonies were counted on the 9th
day. Independent experiments were repeated at least three times.
In Figure 3E, 6 106 CRC cells were mixed with or without 106
MSC cells and then seeded in the co-culture system
(Supplementary Figure 1B). Cells were treated with 10 J cm 2
irradiation for 1 h per 8 h. Total cells in each well were counted at
24 h, 48 h, 72 h, 96 h, and 120 h, respectively.
CFSE cell proliferation assay. CRC cells were collected and
pelleted from the co-culture model 2 (Supplementary Figure B)
from the experiment group and the control group, respectively.
After washed with PBS twice, CRC cells were re-suspended and
incubated with CellTrace CFSE (1:1000 dilution) staining solution
for 20min in dark. Cells were pelleted again and resuspended in
fresh pre-warmed complete culture medium. The results were
analysed by flow cytometry. The experiments were repeated three
times.
ELISA. Culture medium from the co-culture system after irradia-
tion was collected at 6, 12, and 24 h, respectively. Cytokines
concentration was determined by sandwich ELISA using a Human
Th1/Th2/Th17 Cytokines Multi-Analyte ELISArray Kit (Qiagen,
Hilden, Germany), following the manufacturer’s instructions.
Immunoblot analysis. Cells were homogenised and lysed in RIPA
buffer supplemented with proteinase inhibitor. An equal amount of
proteins (25 mg) were loaded and run on 12% SDS-PAGE gel and
transferred onto PVDF membranes following electrophoresis.
After the incubation with 5% milk in TBS/T for 1 h, the membrane
was incubated with the primary antibodies at 4 1C overnight. The
primary antibodies used in this experiment were: anti-total AKT,
anti-total Erk, anti-Phospho-AKT, anti-Phospho Erk1/2, anti-
procaspase 3, anti-Caspase3, anti-PI3K, anti-beta-actin, anti-
GFAP, anti-vimentin, anti-desmin, anti-alpha-smooth muscle
actin, and anti-Phospho Stat3 (Cell signaling, Danvers, MA,
USA). GAPDH (Cell Signaling) was used as the loading control.
Immunofluorescence. Cells cultured in eight-well chamber slides
(Falcon, BD, Germany) and culture-inserts (ibidi) were washed
twice with cold PBS, fixed with 4% para-formaldehyde for
15min, permeabilised with 0.1 % Triton X-100 for 5min, blocked
with 5 % BSA, incubated with indicated primary antibodies:
anti-GFAP and anti-desmin (Sigma, Darmstadt, Germany), anti-
Lgr5 (Abcam, Cambridge, UK), anti-a-SMA, and anti-Vimentin
(R&D, Minneapolis, MN, USA), APC-anti-CD271 (Miltenyi
Biotech, Auburn, CA, USA) at 4 1C overnight and followed by
anti-rabbit Alexa fluor 488 secondary antibody and anti-mouse
Alexa Fluor 568-conjugated secondary antibody (Life technology,
Darmstadt, Germany). The cells were then stained with anti-fade
DAPI (Life Technology) for nuclear staining, and the images were
acquired with an Olympus Axion microscope (Olympus, Tokyo,
Japan).
Flow cytometry. PE-CD133, FITC-CD44 (Biolegend, San Diego,
CA, USA), LGR5, APC-CD271 antibodies were used for flow
cytometry. Take CD133 for example, the expression of CD133
antigen on hybrids and parental CRC cells were performed by flow
cytometry. Cells were stained with PE-conjugated monoclonal
anti-human CD133 (Becton Dickinson, San Jose, CA, USA).
Isotype control IgG-PE, served as a control. After stained 30min,
samples were analysed by flow cytometry (FACS Calibur, BD
Biosciences, San Jose, CA, USA) and data were analysed using
CellQuest software and BD FACSDiva6.0 software (BD Bios-
ciences). Intracellular staining flow cytometry followed the
standard protocol provided by BD. CFSE (Biolegend, San Diego,
CA, USA) and 7-AAD/Annexin V kit (eBioscience, Thermo Fisher
Scientific, Darmstadt, Germany) were used to perform prolifera-
tion assay and cell apoptosis assay.
Selected isolation of MSCs from the co-culture system. Cell
separation from co-culture system was performed using the
CD271þ MicroBeads isolation kit (Miltenyi Biotech) as recom-
mended by the manufacturer. Separation occurs in a MACS
Column, which induces a high-gradient magnetic field (B0.6
Tesla) when placed in an AutoMACS Separator (Miltenyi Biotech).
After the automatic sorting, CD271þ MSCs and CRC cells were
separated in different falcon tubes for further analysis.
Organoid culture. Fresh CRC tissue samples were cut into small
pieces using a scalpel, washed with ice-cold PBS containing
antibiotic 3B5 times, and subsequently digested with 0.05%
trypsin, 0.02% EDTA (Thermo Fisher Scientific, Waltham, MA,
USA) for 12min at 37 1C with shaking every 15min. The
remaining fragments were additionally treated with Collagenase
NB 4G (SERVA Electrophoresis GmbH, Heidelberg, Germany)
at 37 1C for 20min. The pellet was re-suspended in 24ml 40%
Percoll PLUS/Percoll, placed in 50-ml polystyrene conical
centrifuge tube (BD Biosciences) and overlaid with 9ml 70%
Percoll solution. Centrifuge immediately at 2500 rpm (Eppendorf
5810R centrifuge) for 20min (brake off), at room temperature.
The cell fraction was carefully and gently collected above the
interphase band (above 1.065 gml 1) by using a sterile Pasteur
pipet, then pelleted at 1500 rpm (Eppendorf, Hamburg, Germany)
for 7min at 4 1C. The cell pellet was suspended with Matrigel
(growth factor reduced; BD Biosciences) and dispensed into 48-
well culture plates (25ml matrigel per well), which have also cover
with single layer of MSC. The basal culture medium for human
intestinal organoids was prepared as recently described (Fujii et al,
2016).
Analysis of publicly available data sets. To analyse CD271
mRNA expression in colorectal adenocarcinoma, we obtained the
data from TCGA, by using www.cbioportal.org. Specifically, on the
home page of the website, select ‘Query’, then, select ‘Colorectal
Adenocarcinoma (TCGA, Provisional)’, enter CD271 (NGFR) gene
in the ‘enter gene set’, download data from Plots and Survival data,
click ‘mRNA expression Z-score (all genes)’ from Select Genomic
Profiles, the NGFR mRNA Z-scores of 382 cases will appear. To
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Figure 1. Co-cultivation with MSCs promoted colorectal cancer cells (CRC) to obtain stemness in vitro. (A) Human colorectal cancer tissues and
adjacent normal tissues were stained with the anti-CD271 antibody (MSCs marker, yellow). MSCs could be found surrounding the tumour lesions
(200x). (B) Counts of CD271þMSCs of the slides were calculated respectively using ImageJ. MSCs were enriched in tumour site (Red box)
compared with normal tissues (black box). (C) Disease-free survival (DFS) rate was analysed basing on TCGA data set. Patients were separated into
CD271 mRNA z-score high and low groups. (D) Co-cultivation model for MSCs and CRC. The 3.5 cm and 10 cm dish share medium through two
wedge gaps when the medium is enough to reach the level of the wedge gap. If the medium did not reach the wedge gap level, cells in two dishes
could grow independently. FACS analysis of CD133þCRC stem cell-like cells, CD133þCD44þ stem cell-like cells before and after co-cultivation
with MSCs. Three cell lines HT29, SW1116, and SW620 were taken into consideration. (E) Immunofluorescence staining and quantification showed
the proportion of LGR5þCRC stem cell-like cells increased after co-cultured with fibroblast or mesenchymal stromal cells compared with control
group. *Po0.05.
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analyse the effect of NGFR expression on prognostic of CRC
patients, we generated Kaplan–Meier survival curve of CRC
patients with low or high expression of NGFR by using PRISM.
Statistical analysis. All continuous values were expressed as
mean±s.d. and all experiments were repeated three times. The
results were subjected to a nonparametric Mann–Whitney U-test.
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A paired Student’s t-test, unpaired t-test, two-way ANOVA were
also used to analyse the intragroup and intergroup differences. All
statistical analyses were done using GraphPad Prism7 (GraphPad
Software Inc., La Jolla, CA, USA) and Stat View 5.0 for Windows
(SAS Institute Inc., Cary, NC, USA). Student’s t-test was also used
to test differences in cell viability assays. A P-value o0.05 was
considered statistically significant.
RESULTS
The proportion of CRC stem cell-like cells increased when co-
cultured with MSCs. CD271 is a biomarker for mesenchymal
stem/stromal cells and follicular dendritic cells in the colorectal
tumour site. In CRC specimens, the CD271þMSC density (counts
per mm3, n¼ 20) was significantly higher (P¼ 0.037, Figure 1A
and B) than in adjacent normal tissues (5B10 cm from the
proximal tumour margin). Basing on TCGA publicly available data
sets, it was found that high expression of NGFR (CD271) mRNA in
the tumour tissues (mRNA z-score 4 0.3115) was related to
worse disease-free survival (DFS) (Figures 1C, P¼ 0.04,
HR¼ 1.537, 95% CI: 1.014B2.332, n¼ 382). This might suggest
that high density of CD271þMSC is relevant with a poor DFS rate
of the patients. In in vitro experiment, CRC displayed the
morphological characteristics of epithelial–mesenchymal transition
after co-cultured with BM-MSCs for 72 h (Supplementary
Figure 1A). To further identify whether MSC-CRC cell-cell
adhesion was important for this alteration, three different co-
culture models were established. After 72 h co-cultivation in ibidi
m-Dish (module 1, Figure 2F) and wedge-gap dish (module 2,
Figure 1D), flow cytometry showed significantly elevated propor-
tion of CD133þ cells (48 h, 11±3.7 vs 3±1.9%, Po0.05),
CD133þCD44þ cells (Figure 1D, 72 h. 19.74±0.7426 vs
11.73±0.9979, Po0.0001, 95% CI 5.374B10.65,) and Lgr5þ
cells (Figure 1E, 72 h, CRCþ fibroblast, 75±10.8 vs CRCþMSC,
60±3.8 vs MSC, 29±7) in cancer cells from co-cultivation groups.
Cancer cells underwent epithelial-mesenchymal transition and
MSC differentiated into mature cancer-associated fibroblasts
(CAF) in the co-culture model. In the MSC-CRC wound-healing
assay, MSCs showed greater mobility than CRC cells (Supplementary
Figure 1B). Besides, MSCs exhibited a series of morphological
changes, including elongated phenotype, reduced adhesion, and
increased migration, which were normally observed in the
differentiation process of MSCs to CAFs (Direkze et al, 2004).
Immunofluorescence analysis of MSCs which were co-cultured with
CRC cells for 48 h revealed upregulated expression of a-SMA,
whereas downregulated expression of desmin, suggesting the
differentiation of MSCs to fibroblasts (Supplementary Figure 1C
(a–f) D) (Wang et al, 2004). Meanwhile, immunofluorescence
staining of CRC cells revealed up-regulated vimentin, fibronectin,
snail as well as GFAP protein expression and downregulated
E-cadherin expression, indicating the progression of epithelial–
mesenchymal transition (Supplementary Figure 1A, Figure1C, G-I).
CRC cells showed more attenuated proliferation and viability in
the co-culture system than in the non-co-culture system under
irradiation. Though it was found that high density of CD271þ
MSC is relevant with a poor DFS rate of the CRC patients,
however, radiotherapy was not taken into consideration. What is
the function of MSCs when under radiation?
CRC cells (4 104 cells) and MSCs (1 104 cells) were seeded
and cultured in module 2 (module 2, Figure 1D), with CRC cells
(4 104 cells) cultured alone as the control group. Cells were then
irradiated with 10 J cm 2 irradiation for 1 h per 8 h, lasting for
72 h. Viable CRC cells and MSCs in each group were collected and
counted every 12 h, respectively. Proliferation assays were per-
formed in CRC cells. CRC cells from co-culture group showed a
significantly attenuated proliferation capability (Figure 2A and B).
In the 3D colony formation assay, different numbers of CRC
cells (25, 50, 100, and 200 cells) were seeded in ultra-low
attachment plates as the blank control group, additional 25 MSCs
were seed to each well to set up the co-culture group, making the
final CRC: MSC ratio 1:1, 2:1, 4:1, and 8:1. The negative control
group was established by using additional 25 CRC cells instead of
25 MSCs. Cells were then treated with 10 J cm 2 irradiation for 1 h
per 8 h, lasting for 8 days. Cell colonies were counted on the 9th
day (Figure 2C). The negative control group exhibited a
significantly enhanced colony formation capability (psw620¼ 0.035,
psw1116¼ 0.027, pHT29¼ 0.043), especially with CRC:MSC ratio
within 2:1 B4:1 (Figure 2D). Based on these results, we suggest
that the MSCs impaired the proliferation and colony formation
capability of CRC cells under irradiation. Next, we use module 2,
which can include more cells to verify the finding.
Specifically, 6 106 CRC cells and 1 106 MSC cells were
seeded in the inner well and outer well of the co-culture system,
respectively (module 2). The control group was established by
seeding only the same amount of CRC cells in the inner well. Cells
were treated with 10J cm 2 irradiation for 1 h every 8 h. Cell
counts in each well were calculated at 24 h, 48 h, 72 h, 96 h, and
120 h, respectively. The result is consistent with former results.
Especially within 96 h, CRC cell counts declined more rapidly in
the co-culture group than CRC cells alone (Figure 2E). Intrigu-
ingly, the number of viable CRC cells from the co-culture system
stayed stable after 96 h. However, the number of C xRC cells in
the control group was still decreasing (Figure 2E, Supplementary
Figure 1E). Accordingly, this could be owing to that the MSC-
induced part of cancer cells to maintain/gain stemness at the early
Figure 2. Co-culture system showed attenuate proliferation and viability under UV irradiation. (A) This is a representative figure of proliferation
experiment. In total, 4 104 SW1116, HT29 or DanG cells were seeded with or without (control group) 1104 MSCs in 12-well plate. In total,
10 J cm2 irradiation was performed for 1 h and last for 6 h and total cell numbers in each well were counted at 12 h, 36 h, and 72 h respectively.
(B) CSFE assay of control and co-cultivation group. (C, D) 25, 50, 100, or 200 SW1116, SW620 cells were seeded in ultra-low attachment 24-well
plates, respectively (control), or following by additional 25 bone marrow-derived mesenchymal stromal cells seeding in each well. Twenty-five
more SW1116 cells were also seeded instead of 25 MSCs as blank control. After 10 J cm 2 irradiation 1 h per 8 h for 8 days, cell colonies were
counted on the 9th day. Independent experiments were repeated 2B3 times. Mean value were represented. (E) 6 106 SW1116 cells were
seeded in co-culture system (Supplementary Figure 2B), with or without 106 MSC cells seeding in the inserted well. 10 J cm2 irradiation was
performed for 1 h and last for 8 h and total cell numbers in each well were counted at 24 h, 48 h, 72 h, 96 h, and 120h, respectively. The colorectal
cancer cells decreased more rapidly in the co-culture group than control group (SW1116 only) at the beginning (0B96h) after irradiation, however,
turned to be slower and stayed stable after 96 h. (F) Co-culture model for MSCs and CRC. The m–Slide 29 well harbours two arrays of 3 3
square fields where cells can be cultivated independently within the small square or share the same growth medium within the total 33 square
fields. After co-cultivation for 48 h, flow cytometry showed more CD133þCD44þ colorectal cancer stem cell-like cells than the control group.
However, there were also more 7-AADþdead cells compared with the control group. *Po0.05.
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calculating and establishing the heat map. (B–E) To identify the origin of cytokines, MSCs, and CRCs were collected from the irradiated co-culture
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Proportions of cells are shown in column; (D): expression of cytokines in MSC from co-cultivated model before and after irradiation; (E): cytokines
expression of CRC cells in co-cultivated model before and after irradiation; (F): PI3K/AKT signal pathway protein p-Akt and p-Erk1/2 from
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Combined MSC and irradiation in CRC patients BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.415 7
85 KD
100
80
H
is
to
gr
a
m
/c
ou
nt
s
CR
C
CR
C+
M
SC
(di
rec
t c
o-c
ult
ure
)
CRC+MSC
(direct co-culture)
CRC+MSC
(indirect co-culture) CRC
H
is
to
gr
a
m
/c
ou
nt
s
60
40
20
0
100
80
60
40
20
0
PI3K
Akt
p-Akt
p-Erk 1/2
p-Stat3
-actin
Pro-Caspase3
Cleaved
Caspase3
Erk1/2
12 h
CRC
(control)
CRC
(MSC+CRC)
CRC
(Fibroblast+CRC)
12 h 12 h24 h 24 h 24 h48 h 48 h 48 h
37 KD
60 KD
60 KD
44 KD
42 KD
35 KD
19 KD
17 KD
86 KD
42 KD
200 m
a
A
C
D
B
b c
d e f
200 m
100 m
M
er
ge
Ep
ca
m
PI
a b c
fed
100 m 100 m
100 101 102 103 104
100 101 102 103 104
+MSC
–MSC
Control
TNFalpha
IFNgamma
+MSC
–MSC
Control
Figure 4. Co-cultivation showed increased cell death and suppression of AKT signal pathway of colorectal cancer cells under ionising irradiation.
(A) Ionising irradiation could induce TNFa and IFN5 secretion by MSC in the co-cultivated system. (B) Colorectal cancer cell ERK and AKT
signalling pathways were suppressed in the co-cultivated system, meanwhile, cleaved caspase 3, and p-Stat3 in CRC cells were activated in
CRCþMSC co-culture group. (C) The same number of 3D spheroids (CRC cells and CRC cellsþMSCs) were transferred into an ultra-low
attachment plate and treated with 10 J cm2 irradiation for 1 h in every 6 h. Dark cores (red arrow), which were reported to be dead cells, could be
observed in the co-culture group. Tumour organoids were co-cultivated with or without MSCs, the volumes of tumour organoids turned to be
smaller in the cocultivation group (f, a single layer of MSC was seeded below the Matrigel layer) compared with CRC without MSCs feeding after
irradiation. (D) To further confirm the cytotoxicity effect of MSC under irradiation, PI staining was performed on two co-culture models (direct CRC
cells-MSCs contact and indirect co-cultivation), as well as colorectal cancer spheroids. the co-cultivation group, both direct co-cultivation and
indirect co-cultivation showed more dead cells under irradiation even in 3D culture condition.
BRITISH JOURNAL OF CANCER Combined MSC and irradiation in CRC patients
8 www.bjcancer.com |DOI:10.1038/bjc.2017.415
phase of irradiation, thereafter those cancer stem cells-like cells
could be resistant to irradiation. Subsequently, the hypothesis was
further approved by stem cell staining (CRCþMSC vs CRC
Control: 7.533±0.48 vs 0.95±0.23%, Po0.0001, 95% CI,
 7.703B 5.453) and 7-AAD live/dead cell staining via flow
cytometry (Figure 2F).
MSCs secrete IFNg, TNFa when co-cultured with CRC cell
under irradiation. To investigate the reason behind the finding,
we supposed that cytokine alteration induced by MSCs might affect
the CRC cells. To verify the hypotheses, cells grown in the co-
culture system was treated with 10 J cm 2 irradiation for 1 h in
every 6 h. The supernatant was collected afterward at 6 h, 12 h, and
24 h, respectively. ELISA array was performed with the supernatant
and the result was presented in Figure 3A. It reveals that the
supernatant from the co-culture system contained increased
concentration of GM-CSF, which was reported by others. Besides,
elevated TGF-b1, IFNg, and TNFa were also detected. In contrast,
IL13 decreased significantly after the ultraviolet radiation (UV)
irradiation. To investigate the cell origin of TNFa or IFNg, flow
cytometer analysis was performed. We found that it is MSC rather
than CRC cell that is responsible for the secretion of TNFa, IFNg,
and expression of CD154 (also known as CD40L), which can
induce cytotoxicity against CRC (Figure 3B-E).
Phosphorylated AKT (p-Akt) and phosphorylated Erk1/2 were
suppressed in CRC cells from the co-cultured system. Next, we
investigate the change of signal pathways, which are involved in the
cell proliferation by western blot. Specifically, the result revealed
that p-Akt and p-Erk1/2, which are important protein in PI3K/
AKT signal pathway, were significantly suppressed in CRC cells
when co-cultured with MSCs under UV irradiation conditions
(Figure 3F). Taken together, suppression of p-Akt and Erk1/2 in
CRC cells, when incubated with MSC under irradiation, con-
tributes to the arrest of the cell proliferation and cell death.
CRC cells showed increased apoptosis and suppressed AKT
signal pathway in the co-culture system under ionising
irradiation. Subsequently, we investigate the cell apoptosis and
AKT signal pathway in CRC cells in the co-culture system.
Specifically, CRC cells and MSCs were co-cultured and irradiated
under same conditions as described before. Cell death and cell
apoptosis assay showed significantly increased cell death of CRC
cells, especially necrosis of cells in co-culture group. For instance,
SW620 isolated from the co-culture module 2 display significantly
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Figure 5. Schematic representation of colorectal cancer cells apoptosis induced by irradiation treated bone marrow-derived mesenchymal
stromal cells.
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higher proportion of necrotic cells (9.7±1.2 vs 1.6±0.1%) and late
apoptotic cells (2.6±0.8 vs 1.5±0.05%) after irradiation
(P¼ 0.0012). Despite the heterogeneity among different cancer
cell lines, total cell death and necrosis rate of CRC cells were
increased significantly in the co-culture group (Figure 3G). In
consistent with the result of UV irradiation, ionising irradiation
could also induce TNFa and IFNg secretion by MSC in the co-
culture system (TNFa: 13.6 vs 1.2%, Po0.05; IFNg 22.1 vs 4.6%,
Po0.01, Figure 4A). When the co-culture system was treated with
TNFa and IFNg neutralising antibodies, CRC cells displayed
attenuated cell death rate (P¼ 0.03, Figure 3G). Moreover, ERK
and AKT signalling pathways were suppressed while apoptosis
pathway was activated in CRC cells. Interestingly, p-Stat3 was also
activated in CRC cells, which might be the result of feedback
regulation to rescue CRC cells from death (Figure 4B).
CRC cells showed increased apoptosis in the 3D co-culture
system under ionising irradiation. Afterward, the cytotoxicity of
MSC under ionising irradiation was performed in the 3D co-
culture system. CRC cells were co-cultivated with or without MSC
in the hanging-drop plates to form 3D spheroids (direct co-
cultured). The same number of spheroids were then transferred
into a 96-well ultra-low attachment plate and treated with 10J cm-2
irradiation for 1 h in every 6 h. Dark cores, which were reported to
be dead cells, could be observed in the co-culture group
(Figure 4C). Tumour organoids derived from three patients were
also sub-cultured with or without MSC (see Method), the volumes
of tumour organoids turned to be smaller in the co-cultivation
group (Figure 4F) after irradiation. To further confirm the
cytotoxicity effect of MSC under irradiation, immunofluorescence
staining was performed on two co-culture models (direct and
indirect), as well as CRC spheroids. In consistent with our
hypothesis, the co-cultivation group showed more dead cells under
irradiation even in 3D condition (Figure 4D).
DISCUSSION
Radiation therapy could render tumour cells visible to the immune
system of patients. In addition to the direct effects of radiation, the
ensuing immune response orchestrates the expression of inflam-
matory mediators and cytokines, which act on local milieu and
neighbouring tumour cells (Sologuren et al, 2014). Although MSCs
are not originally identified as immune cells, MSCs possesse
various immune regulatory capacities and are pivotal components
in the tumour microenvironment, being able to home and infiltrate
into the tumour stroma. Up to date, results of previous studies are
controversial about its biological interaction with CRC cells,
particularly in terms of promotion versus inhibition of tumour
progress (Guan and Chen, 2013).
In normal tissues, MSCs were observed to be radiation-
protective through its well-known ability of regenerative functions
after ionising radiation (Gao et al, 2012; Li et al, 2013; Nicolay et al,
2015; Wilson et al, 2015). It was proposed that MSC may also be
protective in a similar way for CRC cells after radiation. Thereafter,
some research groups found that after the treatment of MSC-
conditioned medium, breast cancer cells could exhibit elevated
proliferation capability as well as radiation-resistance, owing to the
high levels of insulin-like growth factor-1 in the medium (Yang
et al, 2014). Meanwhile, evidence was also provided that MSC
could induce both inflammatory and immune suppressive micro-
environment (Eterno et al, 2014), indicating that the cytokines, e.g.
G-CSF, IL1a, and TNFa etc., were tightly regulated by environ-
mental challenges (Zhukareva et al, 2010).
In contrast, most recent investigations demonstrated that MSCs
were able to inhibit tumour growth by apoptosis induction (Han
et al, 2014). Moreover, it seems that MSCs, in combination with
irradiation, were able to enhance the systematic anti-tumour effect
of ionising radiation and thus synergistically increase the efficiency
of radiotherapy (de Arau´jo Farias et al, 2015). One of the reasons
might be that radiation-induced acute damage to MSCs and a
perpetual cascade of cytokines triggered the recruitment of
immune cells (Wirsdo¨rfer and Jendrossek, 2016). Intriguingly,
lower doses of irradiation could selectively stimulate the prolifera-
tion of MSCs but not tumour cells in vitro via the activation of
MAPK/ERK signalling pathway (Liang et al, 2011). In addition,
MSCs could also possess superior antioxidant ROS-scavenging
capacity and more active DNA double-strand break repair systems
to facilitate their radioresistance (Chen et al, 2006). In the present
study, we demonstrated that, under a low dose of radiation, MSCs
might improve the anticancer responses by releasing various
cytokines such as IFNg and TNFa and expressing upregulated
CD154, and attenuated the proliferative activity and viability of
CRC cells, producing a potent cytotoxic synergistic effect on CRC
cells. Besides, other groups have found that MSC can express
iNOS, secrete IL-12, IL-2, and other foreign gene-encoded
cytokines to inhibit tumour progress or the proliferation of other
cells (Nakamura et al, 2004; Xiang et al, 2009; Gao et al, 2010;
Zino¨cker and Vaage, 2012; Jeong et al, 2015).
Cell death was just one aspect of cancer biology. Another vital
aspect was the invasion of the cells, which is directly related to
metastasis. To evaluate whether X-ray irradiation lead to increased
metastases, the transwell invasion assay was performed. Though
the CRC and MSC co-culture group showed stronger invasive
capability, there was no difference between CRCþMSC group and
CRC group when cultivated under irradiation.
Furthermore, recent data also suggested that MSCs exhibited
potentials for inhibiting tumour proliferation or spread through
cell cycling arresting and cell death-related signalling pathways
activation (Chang et al, 2015). For example, Khakoo et al reported
that reducing tumour cell growth could be observed ex vivo when
treated with human bone marrow MSC by Akt activity inhibition
of tumour cells (Khakoo et al, 2006). In the present study,
irradiation on the co-culture system induced the cleavage of
caspase3, and attenuated the PI3K/ AKT as well as ERK in cancer
cells. Similarly, it was reported that MSC associated anticancer
effect was mainly by suppressing PI3K/Akt signalling pathway and
subsequently increasing the protein level of cell death factors (Ma
et al, 2012). Specifically, combination of MSCs and radiations
resulted in the cleavages of caspase 9/3, increased phosphorylation
of JNK and decreased phosphorylation of PI3K/AKT and ERK in
cancer cells. Suppression of PI3K/Akt signalling cascades could
lead to the blockade of both cell cycle progression and cell growth
during CRC development. Han et al (2014) reported that JNK
inhibition reversed the apoptotic ability of MSCs to cleave caspase
9/3 in prostate cancer cells, indicating that the JNK pathway might
also be activated when PI3K was suppressed. Aikin et al (2004)
claimed that suppression of PI3K was the reason of increased JNK
phosphorylation and cell death. Many mechanisms might be
involved in the suppression of PI3K/Akt signalling pathway, e.g.,
cytokines (IGF-1, TNFa et al) (Liu et al, 2017), PTEN over-
expression, and miRNA. Concerning the cytokines, though it was
reported that TNFa could inhibit the apoptosis of several cancer
cells by inducing the phosphorylation of Akt at both Ser473 and
Thr308, the switch of promoting or inhibiting apoptosis effect was
mainly dependent on the concentration of TNFa (Sandra et al,
2002). Other mechanisms included ROS-induced PI3K/Akt
signalling pathway activation and radiation-associated bystander
effect of MSCs on CRCs. Radiation-induced bystander effect is to
descript the phenomenon that cells which exposed to irradiation
could communicate their DNA damage response condition to
bystander cells, which have not been directly irradiated. Cytokines
induced ROS-production (Schaue et al, 2012), Activation of NF-c¸B
signalling pathway, and NF-c¸B induced enzymatic systems like
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iNOS were suggested to be the molecular underpinnings of this
bystander effect (Han et al, 2003).
In co-culture experiments without UV irradiation, we found that
MSCs prompted the epithelial-mesenchymal-transition and CRC
cell stemness. Similarly, Xue JG et al reported that co-culture of
gastric cancer cells and umbilical cord MSCs increased the
expression of stemness factors and EMT markers, such as
N-cadherin, Vimentin, a-SMA, and fibroblast activation protein,
in gastric cancer cells (Direkze et al, 2004; Xue et al, 2015) Though
MSC was important in promoting an inflammatory and immune
suppression microenvironment, the function of MSCs was also
interfered by the tumour microenvironment. In this study, we also
observed an elevated expression of TGF-b, particularly at the early
phase of post-irradiation, in the supernatant of the co-culture model.
We verified that elevated expressions of TGF-b could promote the
differentiation of MSCs to CAFs (Wang et al, 2004; Quante et al,
2011). Similarly, other groups have reported that TGF-b can
stimulate hypomethylation of MSCs and induce gene expression
profiles alterations towards myofibroblast signature-expressing
biomarkers. However, the limitation of this study is lack of in vivo
perspective. Concerning preclinical situation, the study from de
Arau´jo Farias et al might give a clue. They reported that in vitro
MSCs are a source of anti-tumour cytokines after a low dose of
irradiation, MSCs decreased the proliferative activity of tumour cells,
producing a potent cytotoxic synergistic effect on tumour cells
(Direkze et al, 2004; de Arau´jo Farias et al, 2015; Xue et al, 2015).
It was recently demonstrated that radiations might induce
senescence of MSCs which affect the functions. Consequently,
senescent cells could block the proliferation of cancer cells and
induced apoptosis (O¨zcan et al, 2015, 2016; Alessio et al, 2017).
Thus, we performed the acid b-galactosidase assay. Cells were
irradiated with the total dose of 10Gy. We found the proportion of
senescent MSCs was increasing after the irradiation (P¼ 0.037)
(Supplementary Figure 2A). However, when we incubated the
cancer cells with the conditional medium from control or
senescent MSC, there was no significant effect on CRC cells by
acid b-galactosidase staining. Secretomes and exosomes had an
important role in anti-tumour activities. However, in the present
study, the effect was not significant. It might be owing to the effect
becoming impaired when secretomes were collected from senes-
cent cells previously in contact with cancer cells as reported before
(O¨zcan et al, 2015; Alessio et al, 2017).
Concerning the limitations of this study, the in-vivo experiment
needs to be further performed to verify not only the therapeutic
achievement but also bystander effects of MSCs administration in
CRC patients. In addition, concerning the similarities and
differences between of UV-C and X-ray in the present study, for
UV radiation, the main damages are on the same DNA strand.
However, X-rays induced both single and double strand breaks.
Another difference is that the X-rays are more penetrating, which
is also why they are used in radiation oncology. However, the
similarities could be found even at the beginning of the signalling
response cascade. Both these damages allow the phosphorylation of
histone variant 2AX and form characteristic ‘repair foci’. UV and
ionising irradiation were used together in lots of studies
(Aszterbaum et al, 1999). Because both UV and ionising radiation
(IR) produce oxidised bases DNA damage, they could also elicit
complex cellular responses involving several similar signalling
pathways, for example, NF-c¸B signalling pathway, MAPK signal-
ling pathway, PI3K/AKT signalling pathway, and ROS-associated
signalling pathways (Rieger and Chu, 2004).
Because MSC differentiated into CAF during the cocultivation
with tumour cells, it is important to examine the BM-MSCs as a
function of time: before and after this differentiation occurs.
It was reported that the CAF associated genes such as SDF-1,
CCL2, MMP9, and PDGFRB were upregulated in the 30-day tumour
conditional media exposed MSC. Most of the top 25 upregulated
genes were involved in glycoprotein and binding process and in
cellular metabolism. (Mishra et al, 2008). Those CAF-like cells could
stimulate tumour survival and proliferation, angiogenesis, and
metastatic spread in xenograft models (Guilloton et al, 2012).
Concerning the clinical setting, the time period might change
the treatment strategy. In brief, it took more or less 5–6 weeks.
However, the functional consequence of MSC plus radiation is
controversial. The detailed properties of radiation-surviving
endogenous MSCs are not well documented in human and animal
studies. It is generally agreed that the physiologic properties of
surviving MSCs after a life-threatening dose of radiation are more
likely to differ significantly from those before radiation exposure,
despite their having an active DNA damage responding pathway.
Even the anti-fibrotic or pro-fibrotic effect is still not certain, from
one hand, MSC could stimulate the cell proliferation of fibroblast
and modulate relevant soluble mediators and proteinases after
external radiation (Haubner et al, 2015), on the other hand, the
post-irradiation injection of MSC could induce host secretion of
HGF and PGE2 to control the activation of fibroblasts. To
summary, the effects differ a lot owing to the various models and
dose setting. Thus, to establish a standard, more clinically relevant
model to evaluate the effect of MSC as well as radiation is essential.
The present study is just offering evidence from one perspective.
Taken together, this study provided a possibility to enhance the
anti-tumour effect of radiotherapy by utilising MSCs treatment.
(Figure 5). When irradiated with low-dose irradiation, BM-MSCs
show an anti-tumour effect by secreting cytokines like TNF-a, IFN-
g that lead to the inhibition of proliferation and induction of
apoptosis of CRC cells. In addition, suppression of PI3K/AKT
signal pathway proteins p-Akt and Erk1/2 in CRC cells also
contributed to the arrest of cancer cell proliferation and cell death
under irradiation when incubated with MSC.
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Current work 
Hepatic resident iNKT cells recruitment and immune microenvironment 
modulation in colorectal liver metastasis 
Aim:  The aim of this ongoing study is to investigate the modulatory effect of the hepatic 
immune microenvironment by the crosstalk of hepatic resident iNKT cells and Kupffer 
cell as well as dendritic cells in hepatic metastases of colorectal cancer. 
Methods: Various of sub-classification of iNKT cells, Kupffer cell as well as dendritic 
cells located in the core of tumor, cancer invasive margin, as well as adjacent normal 
hepatic tissue were detected and analyzed by BD flow cytometry (LSR Fortessa™), 
immunofluorescence, and colorectal malignancy tissue microarray(n=138). Ex vivo 3D 
co-cultivation simulation and Quansys Multiplex assay were also performed. 
Interim results: In metastatic status, CXCR6 positive iNKT cells had a positive 
correlation with long term outcome. Additionally, iNKT cells, especially type 2 iNKT cells 
(NKT2) were enriched at the invasive margin. Interestingly, despite less iNKT cells 
presenting at the core of tumor, the proportion of iNKT cells out of lymphocytes elevated 
to appropriate five folds and expressed enhanced IFNγ, IL9, and FasL compared to 
normal hepatic tissue and invasive margin. This implied the vital role of iNKT cells in 
immunological surveillance. Both dendritic cells and Kupffer cells had the capability to 
promote iNKT cells activation, the proportion of BDCA-3+DCs dramatically increased 
from normal tissue to the core of the tumor. Though BDCA-3+DCs expressing an 
enhanced level of CXCL16 comparing to other subtypes, the competency of CD1d 
mediated iNKT activation was inferior to plasmacytoid DC. Plasmacytoid DC expressed 
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with significantly higher α-GalCer: CD1d complex formation in ex vivo assays, implying 
the vital role of pDC in NKT activation. In the present study, Kupffer cells also showed 
the potential to awaken iNKT cells. Intriguingly, iNKT released Th2 cytokines when 
activated by Kupffer cells. On contrast, Th1 biased immune response might be detected 
when NKT cells were activated by dendritic cells. Furthermore, KC subtypes also 
differed from location to location. Additionally, transmembrane CD1d expression, 
intra/tmCXCL16 expression, and Th1/2/17 biased immune responses of Kupffer cells 
and dendritic cells were related to lipid metabolism preferences of these cells. 
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"The task of science is to stake out the limits of the knowable, and to center 
consciousness within them." 
1849, R. Virchow, Der Mensch 
 
